PetIQ, Inc. - Quarter Report: 2020 September (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-38163

PetIQ, Inc.

(Exact name of registrant as specified in its charter)


Delaware	35-2554312
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

923 S. Bridgeway Pl.	83616
Eagle, Idaho	(Zip Code)
(Address of principal executive offices)

208-939-8900

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Class A Common Stock, $0.001 par value	PETQ	The Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻	Accelerated filer ⌧

Non-accelerated filer ◻	Smaller reporting company☐

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ⌧ No

As of November 6, 2020, we had 25,286,211 shares of Class A common stock and 3,410,429 shares of Class B common stock outstanding.

Table of Contents

PetIQ, Inc.

Table of Contents


			Page

Part I.	Financial Information		3

	Item 1.	Condensed Consolidated Financial Statements (Unaudited)
		PetIQ, Inc. Condensed Consolidated Balance Sheets	3
		PetIQ, Inc. Condensed Consolidated Statements of Operations	4
		PetIQ, Inc. Condensed Consolidated Statements of Comprehensive (Loss) Income	5
		PetIQ, Inc. Condensed Consolidated Statements of Cash Flows	6
		PetIQ, Inc. Condensed Consolidated Statements of Equity	8
		PetIQ, Inc. Notes to Condensed Consolidated Financial Statements	10
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	49
	Item 4.	Controls and Procedures	49

Part II.	Other Information

	Item 1.	Legal Proceedings	51
	Item 1A.	Risk Factors	51
	Item 6.	Exhibits	52

Signatures			53

Table of Contents

PetIQ, Inc.

Condensed Consolidated Balance Sheets

(Unaudited, in 000’s except for per share amounts)



	September 30, 2020		December 31, 2019
Current assets
Cash and cash equivalents	$	57,753	$	27,272
Accounts receivable, net		100,826		71,377
Inventories		83,880		79,703
Other current assets		5,525		7,071
Total current assets		247,984		185,423
Property, plant and equipment, net		60,409		52,525
Operating lease right of use assets		19,498		20,785
Deferred tax assets		—		59,780
Other non-current assets		1,977		3,214
Intangible assets, net		217,367		119,956
Goodwill		230,872		231,045
Total assets	$	778,107	$	672,728
Liabilities and equity
Current liabilities
Accounts payable	$	65,352	$	51,538
Accrued wages payable		12,552		9,082
Accrued interest payable		2,530		83
Other accrued expenses		8,212		3,871
Current portion of operating leases		4,718		4,619
Current portion of long-term debt and finance leases		7,717		3,821
Total current liabilities		101,081		73,014
Operating leases, less current installments		15,338		16,580
Long-term debt, less current installments		355,495		251,376
Finance leases, less current installments		3,252		3,331
Other non-current liabilities		965		117
Total non-current liabilities		375,050		271,404
Commitments and contingencies (Note 13)
Equity
Additional paid-in capital		349,524		300,120
Class A common stock, par value $0.001 per share, 125,000 shares authorized; 25,256 and 23,554 shares issued and outstanding, respectively		25		23
Class B common stock, par value $0.001 per share, 100,000 shares authorized; 3,420 and 4,752 shares issued and outstanding, respectively		3		5
Accumulated deficit		(82,959)		(15,903)
Accumulated other comprehensive loss		(1,247)		(1,131)
Total stockholders' equity		265,346		283,114
Non-controlling interest		36,630		45,196
Total equity		301,976		328,310
Total liabilities and equity	$	778,107	$	672,728

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

PetIQ, Inc.

Condensed Consolidated Statements of Operations

(Unaudited, in 000’s except for per share amounts)


	For the Three Months Ended				For the Nine Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019

Product sales	$	150,063	$	161,534	$	580,650	$	482,224
Services revenue		12,020		24,491		35,193		72,871
Total net sales		162,083		186,025		615,843		555,095
Cost of products sold		116,847		140,839		469,095		416,748
Cost of services		12,968		17,895		40,142		51,426
Total cost of sales		129,815		158,734		509,237		468,174
Gross profit		32,268		27,291		106,606		86,921
Operating expenses
General and administrative expenses		35,562		29,345		105,744		74,333
Contingent note revaluations gain		—		2,310		—		3,090
Operating (loss) income		(3,294)		(4,364)		862		9,498
Interest expense, net		(7,829)		(5,742)		(18,500)		(9,921)
Foreign currency loss, net		(251)		—		(126)		(73)
Other income, net		13		6		702		21
Total other expense, net		(8,067)		(5,736)		(17,924)		(9,973)
Pretax net loss		(11,361)		(10,100)		(17,062)		(475)
Income tax (expense) benefit		(53,168)		1,304		(52,060)		(77)
Net loss		(64,529)		(8,796)		(69,122)		(552)
Net loss attributable to non-controlling interest		(1,468)		(2,906)		(2,067)		(88)
Net loss attributable to PetIQ, Inc.	$	(63,061)	$	(5,890)	$	(67,055)	$	(464)
Net (loss) income per share attributable to PetIQ, Inc. Class A common stock
Basic	$	(2.53)	$	(0.26)	$	(2.75)	$	(0.02)
Diluted	$	(2.53)	$	(0.26)	$	(2.75)	$	(0.02)
Weighted Average shares of Class A common stock outstanding
Basic		24,935		22,974		24,365		22,387
Diluted		24,935		22,974		24,365		22,387

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

PetIQ, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited, in 000’s)


	For the Three Months Ended				For the Nine Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Net loss	$	(64,529)	$	(8,796)	$	(69,122)	$	(552)
Foreign currency translation adjustment		451		(273)		(227)		(302)
Comprehensive loss		(64,078)		(9,069)		(69,349)		(854)
Comprehensive (loss) income attributable to non-controlling interest		(1,402)		(2,945)		(2,096)		(141)
Comprehensive loss attributable to PetIQ	$	(62,676)	$	(6,124)	$	(67,253)	$	(713)

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

PetIQ, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited, in 000’s)


	For the Nine Months Ended September 30,
	2020		2019
Cash flows from operating activities
Net loss	$	(69,122)	$	(552)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization of intangible assets and loan fees		20,942		11,005
Termination of supply agreement		7,801		—
Gain on disposition of property, plant, and equipment		(363)		(25)
Stock based compensation expense		6,549		4,747
Deferred tax adjustment		52,060		37
Contingent note revaluation		—		3,090
Other non-cash activity		143		146
Changes in assets and liabilities
Accounts receivable		(29,777)		(41,684)
Inventories		(3,993)		12,137
Other assets		3,449		1,368
Accounts payable		15,824		1,026
Accrued wages payable		3,443		2,401
Other accrued expenses		6,863		(2,299)
Net cash provided by (used in) operating activities		13,819		(8,603)
Cash flows from investing activities
Proceeds from disposition of property, plant, and equipment		429		70
Purchase of property, plant, and equipment		(17,811)		(5,128)
Purchase of Capstar and related intangibles		(96,072)		—
Business acquisitions (net of cash acquired)		—		(185,090)
Net cash used in investing activities		(113,454)		(190,148)
Cash flows from financing activities
Proceeds from issuance of convertible notes - liability component		90,465		—
Proceeds from issuance of convertible notes - equity component		53,285		—
Payment for Capped Call options		(14,821)		—
Proceeds from issuance of long-term debt		668,675		661,084
Principal payments on long-term debt		(667,511)		(511,681)
Payment of financing fees on Convertible Notes		(5,884)		—
Tax distributions to LLC Owners		(46)		(1,641)
Principal payments on finance lease obligations		(1,252)		(1,103)
Payment of deferred financing fees and debt discount		(550)		(5,362)
Tax withholding payments on Restricted Stock Units		(313)		—
Exercise of options to purchase class A common stock		8,188		1,588
Net cash provided by financing activities		130,236		142,885
Net change in cash and cash equivalents		30,601		(55,866)
Effect of exchange rate changes on cash and cash equivalents		(120)		(39)
Cash and cash equivalents, beginning of period		27,272		66,360
Cash and cash equivalents, end of period	$	57,753	$	10,455

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

PetIQ, Inc.

Condensed Consolidated Statements of Cash Flows, Continued

(Unaudited, in 000’s)


	For the Nine Months Ended September 30,
Supplemental cash flow information	2020		2019
Interest paid	$	12,311	$	9,472
Net change in property, plant, and equipment acquired through accounts payable		874		(380)
Finance lease additions		993		535
Deferred tax liability created by convertible debt issuance		(8,134)		—
Net change of deferred tax asset from step-up in basis		—		9,517
Income taxes paid, net of refunds		63		216
Accrued tax distribution		(443)		103
Issuance of note for termination, settlement, and asset acquisition agreement		17,487		—

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

PetIQ, Inc.

Condensed Consolidated Statements of Equity

(Unaudited, in 000’s)


	Three months ended September 30, 2020
			Accumulated
			Other										Additional
	Accumulated		Comprehensive										Paid-in		Non-controlling		Total
	Deficit		Loss		Class A Common				Class B Common				Capital		Interest		Equity
					Shares		Dollars		Shares		Dollars
Balance - June 30, 2020	$	(19,897)	$	(1,774)		24,658	$	24		3,770	$	4	$	344,270	$	40,464	$	363,091
Exchange of LLC Interests held by LLC Owners		—		142		350		0		(350)		—		2,958		(3,100)		—
Equity component of Convertible Notes, net of offering costs and tax		—		—		—		—		—		—		212		(358)		(146)
Increase in deferred tax asset from LLC Interest transactions		—		—		—		—		—		—		3,252		—		3,252
Establishment of valuation allowance related to the deferred tax assets from LLC Interest transactions		—		—		—		—		—		—		(9,038)		—		(9,038)
Accrued tax distributions		—		—		—		—		—		—		—		752		752
Other comprehensive income		—		385		—		—		—		—		—		66		451
Stock based compensation expense		—		—		—		—		—		—		1,874		273		2,147
Exercise of Options to purchase Common Stock		—		—		245		0		—		—		6,017		—		6,017
Issuance of stock vesting of RSU's, net of tax withholdings		—		—		3		—		—		—		(21)		—		(21)
Net loss		(63,062)		—		—		—		—		—		—		(1,468)		(64,529)
Balance - September 30, 2020	$	(82,959)	$	(1,247)		25,256	$	25		3,420	$	3	$	349,524	$	36,630	$	301,976


	Nine months ended September 30, 2020
			Accumulated
			Other										Additional
	Accumulated		Comprehensive										Paid-in		Non-controlling		Total
	Deficit		Loss		Class A Common				Class B Common				Capital		Interest		Equity
					Shares		Dollars		Shares		Dollars
Balance - January 1, 2020	$	(15,903)	$	(1,131)		23,554	$	23		4,752	$	5	$	300,120	$	45,196	$	328,310
Exchange of LLC Interests held by LLC Owners		—		82		1,332		1		(1,332)		(1)		11,806		(11,888)		—
Equity component of Convertible Notes, net of offering costs and tax		—		—		—		—		—		—		36,809		6,161		42,970
Payment for capped call share options		—		—		—		—		—		—		(12,696)		(2,125)		(14,821)
Net increase in deferred tax asset from LLC Interest transactions		—		—		—		—		—		—		9,038		—		9,038
Establishment of valuation allowance related to the deferred tax assets from LLC Interest transactions		—		—		—		—		—		—		(9,038)		—		(9,038)
Accrued tax distributions		—		—		—		—		—		—		—		443		443
Other comprehensive income		—		(198)		—		—		—		—		—		(29)		(227)
Stock based compensation expense		—		—		—		—		—		—		5,610		939		6,549
Exercise of Options to purchase Common Stock		—		—		345		0		—		—		8,188		—		8,188
Issuance of stock vesting of RSU's, net of tax withholdings		—		—		25		—		—		—		(313)		—		(313)
Net loss		(67,056)		—		—		—		—		—		—		(2,067)		(69,122)
Balance - September 30, 2020	$	(82,959)	$	(1,247)		25,256	$	25		3,420	$	3	$	349,524	$	36,630	$	301,976

Note that certain figures shown in the tables above may not recalculate due to rounding.

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

PetIQ, Inc.

Condensed Consolidated Statements of Equity (continued)

(Unaudited, in 000’s)


	Three months ended September 30, 2019
		Retained	Accumulated
		Earnings/	Other										Additional
	Accumulated		Comprehensive										Paid-in		Non-controlling		Total
	Deficit		Loss		Class A Common				Class B Common				Capital		Interest		Equity
					Shares		Dollars		Shares		Dollars
Balance - June 30, 2019	$	976	$	(1,327)		22,750	$	22		5,462	$	7	$	282,343	$	56,157	$	338,178
Exchange of LLC Interests held by Continuing LLC Owners		—		(100)		505		1		(505)		(1)		4,951		(4,851)		—
Net increase in deferred tax asset from LLC Interest transactions		—		—		—		—		—		—		3,424		—		3,424
Accrued tax distributions		—		—		—		—		—		—		—		949		949
Other comprehensive loss		—		(234)		—		—		—		—		—		(39)		(273)
Stock based compensation expense		—		—		—		—		—		—		1,302		299		1,601
Exercise of Options to purchase Common Stock		—		—		43		—		—		—		790		—		790
Issuance of stock for vesting of RSU's		—		—		3		—		—		—		—		—		—
Net income		(5,890)		—		—		—		—		—		—		(2,906)		(8,796)
Balance - September 30, 2019	$	(4,914)	$	(1,661)		23,302	$	23		4,957	$	5	$	292,810	$	49,610	$	335,873




	Nine months ended September 30, 2019
		Retained	Accumulated
		Earnings/	Other										Additional
	(Accumulated		Comprehensive										Paid-in		Non-controlling		Total
	Deficit)		Loss		Class A Common				Class B Common				Capital		Interest		Equity
					Shares		Dollars		Shares		Dollars
Balance - January 1, 2019	$	(4,450)	$	(1,316)		21,620	$	22		6,547	$	7	$	262,219	$	64,496	$	320,977
Exchange of LLC Interests held by Continuing LLC Owners		—		(96)		1,590		1		(1,590)		(2)		15,759		(15,663)		—
Net increase in deferred tax asset from LLC Interest transactions		—		—		—		—		—		—		9,517		—		9,517
Accrued tax distributions		—		—		-		—		—		—		—		(103)		(103)
Other comprehensive loss		—		(249)		—		—		—		—		—		(53)		(302)
Stock based compensation expense		—		—		—		—		—		—		3,727		1,020		4,747
Exercise of Options to purchase Common Stock		—		—		81		—		—		—		1,588		—		1,588
Issuance of stock for vesting of RSU's		—		—		11		—		—		—		—		—		—
Net income		(464)		—		—		—		—		—		—		(88)		(552)
Balance - September 30, 2019	$	(4,914)	$	(1,661)		23,302	$	23		4,957	$	5	$	292,810	$	49,610	$	335,873

Note that certain figures shown in the tables above may not recalculate due to rounding.

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

PetIQ Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)

Note 1 – Principal Business Activity and Significant Accounting Policies

Principal Business Activity and Principles of Consolidation

PetIQ, Inc. (“PetIQ,” the “Company,” “we” or “us”) is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. We engage with customers through more than 60,000 points of distribution across retail, including veterinary, and e-commerce channels with our branded distributed medications, which is further supported by our own world-class medication manufacturing facility in Omaha, Nebraska. Our national service platform, VIP Petcare (“VIP”), operates in over 3,400 retail partner locations in 41 states, providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.

We have two reporting segments: (i) Products; and (ii) Services. The Products segment consists of our manufacturing and distribution business. The Services segments consists of veterinary services, and related product sales, provided by the Company directly to consumers.

We are the sole managing member of PetIQ Holdings, LLC (“HoldCo”), a Delaware limited liability company, which is the sole member of PetIQ, LLC (“Opco”) and, through Holdco, operate and control all of the business and affairs of Opco.

The condensed consolidated financial statements as of September 30, 2020 and December 31, 2019 and for the three and nine months ended September 30, 2020 and 2019 are unaudited. The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2019 and related notes thereto included in the most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 11, 2020. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant, and equipment and intangible assets; the valuation of property, plant, and equipment, intangible assets and goodwill, the valuation of assets and liabilities in connection with acquisitions, the valuation of deferred tax assets, the valuation of inventories, liability and equity allocation of convertible notes, and reserves for legal contingencies.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Table of Contents

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.

The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, are at cost, which approximates fair value due to their relatively short maturities. The Notes Payable – VIP Acquisition are carried at cost, which approximates fair value. Our term loan and revolving credit facility bear interest at a variable interest rate plus an applicable margin and, therefore, carrying amounts approximate fair value.

A portion of the purchase price for the acquisition of VIP, (the “VIP Acquisition”) was structured in the form of Contingent Notes (the “Contingent Notes”) that vested based on the combined Company EBITDA targets for the years ending December 31, 2018 and 2019. The combined Company EBITDA targets were met for each year end, and as such the Contingent Notes were earned. As such, the portion of the liability as it relates to each Contingent Note became fixed as of December 31, 2019 and 2018, and are carried at cost, which approximates fair value as the stated interest rate is consistent with current market rates. See Note 2 – “Business Combinations and Asset Acquisitions” for more information regarding the VIP Acquisition.

The Contingent Notes are included in long-term debt in the accompanying condensed consolidated balance sheets. The Contingent Notes began bearing interest at a fixed rate of 6.75% once they were earned, with the balance payable in July of 2023.

The following table summarizes the Level 3 activity related to the Contingent Notes for the nine months ended September 30, 2019:


$'s in 000's
Balance at beginning of the period	$	2,680
Change in fair value of contingent consideration		3,090
Balance at the end of the period	$	5,770

Cash and Cash Equivalents

Cash equivalents consist of highly liquid investments with an original maturity of three months or less at the date of acquisition. All credit card, debit card and electronic transfer transactions that process in less than seven days are classified as cash and cash equivalents. The Company maintains its cash accounts in various deposit accounts, the balances of which at times exceeded federal deposit insurance limits during the periods presented.

Receivables and Credit Policy

Trade receivables due from customers are uncollateralized customer obligations due under normal trade terms generally requiring payment within 45 days from the invoice date. Accounts receivable are stated at the amount billed to the customer, net of discounts and estimated deductions. The Company does not have a policy for charging interest on overdue customer account balances. The Company provides an allowance for credit losses equal to expected losses. The Company’s estimate is based on historical collection experience, a review of the current status of trade accounts receivable, and known current economic conditions including the current and expected impact of COVID-19. Payments of trade receivables are allocated to the specific invoices identified on the customer's remittance advice.

Other receivables consists of various receivables due from vendors, banking partners, and notes receivable from suppliers.

Accounts receivable consists of the following as of:

Table of Contents


$'s in 000's	September 30, 2020		December 31, 2019
Trade receivables	$	95,321	$	67,551
Other receivables		6,068		4,257
		101,389		71,808
Less: Allowance for credit losses		(563)		(431)
Total accounts receivable, net	$	100,826	$	71,377

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined on the first-in first-out (“FIFO”) method and includes estimated rebate amounts. The Company maintains reserves for estimated obsolete or unmarketable inventory based on the difference between the cost of inventory and its estimated net realizable value. In estimating the reserves, management considers factors such as excess or slow-moving inventories, product expiration dating, and market conditions. Changes in these conditions may result in additional reserves. Major components of inventories consist of the following as of:


$'s in 000's	September 30, 2020		December 31, 2019
Raw materials	$	14,088	$	10,675
Work in progress		1,476		1,717
Finished goods		68,316		67,311
Total inventories	$	83,880	$	79,703

Property, Plant, and Equipment

Property, plant, and equipment are recorded at cost. Expenditures for improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation and amortization is calculated using the straight-line method, based on estimated useful lives of the assets, except for leasehold improvements and finance leased assets which are depreciated over the shorter of the expected useful life or the lease term. Depreciation and amortization expense is recorded in cost of sales and general and administrative expenses in the condensed consolidated statements of operations, depending on the use of the asset. The estimated useful lives of property, plant, and equipment are as follows:


Computer equipment and software			3 years
Vehicle and vehicle accessories			3-5 years
Buildings			33 years
Equipment			2-15 years
Leasehold improvements			2-15 years
Furniture and fixtures			5-10 years

Convertible Debt

We separately account for the liability and equity components of convertible debt instruments that can be settled in cash by allocating the proceeds from issuance between the liability component and the embedded conversion option in accordance with accounting for convertible debt instruments that may be settled in cash (including partial cash settlement) upon conversion. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the proceeds from the convertible debt issuance and the amount measured as the liability component is recorded as the equity component with a corresponding discount recorded on the debt. We recognize amortization of the resulting discount using the effective interest method as interest expense in our consolidated

Table of Contents

statements of operations. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.

On May 19^th, 2020, we issued $143.8 million aggregate principal amount of Convertible Notes due 2026 (the “Notes”). See Note 5 – “Debt”. We have allocated issuance costs to the liability and equity components. Issuance costs attributable to the liability component are being amortized to expense over the respective term of the Notes, and issuance costs attributable to the equity component were netted with the respective equity component in additional paid-in capital. Simultaneously, with the issuance of the Notes, we bought capped call options from certain financial institutions to minimize the impact of potential dilution of our Class A common stock upon conversion of the Notes. The premium for the capped call options was recorded as additional paid-in capital in our condensed consolidated balance sheets as the options are settleable in our Class A common stock.

Revenue Recognition

When Performance Obligations Are Satisfied

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations are product sales and the delivery of veterinary services.

Revenue is generally recognized for product sales on a point in time basis when product control is transferred to the customer. In general, control transfers to the customer when the product is shipped or delivered to the customer based upon applicable shipping terms, as the customer can direct the use and obtain substantially all of the remaining benefits from the asset at this point in time.

The Company determined that certain products manufactured to a customer’s specifications do not have an alternative future use at a reasonable profit margin due to costs associated with reworking, transporting and repackaging these products. These products are produced subject to purchase orders that include an enforceable right to payment. Therefore the Company determined that revenue on these products would be recognized over time, as the products are produced. This represents a minor subset of the products the Company manufactures.

Revenue is recognized for services at the time the service is delivered. Customer contracts generally do not include more than one performance obligation. When a contract does contain more than one performance obligation, we allocate the contract’s transaction price to each performance obligation based on its relative standalone selling price. The standalone selling price for each distinct good is generally determined by directly observable data.

Incentives in the form of cash paid to the customer (or a reduction of a customer cash payment to us) typically are recognized as a reduction of sales unless the incentive is for a distinct benefit that we receive from the customer (e.g., advertising or marketing).

The performance obligations in our contracts are satisfied within one year. As such, we have not disclosed the transaction price allocated to remaining performance obligations as of September 30, 2020.

Significant Payment Terms

Our customer contracts identify the product, quantity, price, payment and final delivery terms. Payment terms usually include early pay discounts. We grant payment terms consistent with industry standards. Although some payment terms may be more extended, no terms beyond one year are granted at contract inception. As a result, we do not adjust the promised amount of consideration for the effects of a significant financing component because the period between our transfer of a promised good or service to a customer and the customer’s payment for that good or service will be one year or less.

Table of Contents

Shipping

All shipping and handling costs associated with outbound freight are accounted for as fulfillment costs and are included in the cost of sales. This includes shipping and handling costs after control over a product has transferred to a customer.

Variable Consideration

In addition to fixed contract consideration, most contracts include some form of variable consideration. The most common forms of variable consideration include discounts, rebates, and sales returns and allowances. Variable consideration is treated as a reduction in revenue when product revenue is recognized. Depending on the specific type of variable consideration, we use either the expected value or most likely amount method to determine the variable consideration. We believe there will not be significant changes to our estimates of variable consideration when any related uncertainties are resolved with our customers. The Company reviews and updates its estimates and related accruals of variable consideration each period based on the terms of the agreements, historical experience, and any recent changes in the market. Any uncertainties in the ultimate resolution of variable consideration due to factors outside of the Company’s influence are typically resolved within a short timeframe therefore not requiring any additional constraint on the variable consideration.

Trade marketing expense, consisting primarily of customer pricing allowances and merchandising funds are offered through various programs to customers and are designed to promote our products. They include the cost of in-store product displays, feature pricing in retailers' advertisements and other temporary price reductions. These programs are offered to our customers both in fixed and variable (rate per case) amounts. The ultimate cost of these programs depends on retailer performance and is subject to management estimates.

Certain retailers require the payment of product introductory fees in order to obtain space for the Company's products on the retailer's store shelves. This cost is typically a lump sum and is determined using the expected value based on the contract between the two parties.

Both trade marketing expense and product introductory fees are recognized as reductions of revenue at the time the transfer of control of the associated products occurs. Accruals for expected payouts, or amounts paid in advance, under these programs are included as accounts payable or other current assets in the Condensed Consolidated Balance Sheets.

Warranties & Returns

PetIQ provides all customers with a standard or assurance type warranty. Either stated or implied, the Company provides assurance the related products will comply with all agreed-upon specifications and other warranties provided under the law. No significant services beyond an assurance warranty are provided to customers.

The Company does not grant a general right of return. However, customers may return defective or non-conforming products. Customer remedies may include either a cash refund or an exchange of the product. As a result, the right of return and related refund liability is estimated and recorded as a reduction in revenue. This return estimate is reviewed and updated each period and is based on historical sales and return experience.

Contract balances

Contract asset and liability balances as of September 30, 2020 and December 31, 2019 are immaterial. The Company does not have significant deferred revenue or unbilled receivable balances.

Cost of Services

Cost of Services are comprised of all service and product costs related to the delivery of veterinary services, including but not limited to, salaries of veterinarians, technicians and other clinic based personnel, transportation and delivery costs, rent, occupancy costs, supply costs, depreciation and amortization of clinic assets, certain marketing and promotional expenses and costs of goods sold.

Table of Contents

Research and Development and Advertising Costs

Research and development and advertising costs are expensed as incurred and are included in general and administrative expenses. Research and development costs amounted to $0.6 million and $0.2 million for three months ended September 30, 2020 and 2019, respectively, and $2.5 million and $0.4 million for the nine months ended September 30, 2020 and 2019, respectively. Advertising costs were $5.8 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively, and $8.3 million and $3.5 million for the nine months ended September 30, 2020 and 2019, respectively.

Collaboration Agreements

On July 8, 2019, the Company, through Opco, completed the acquisition of all the outstanding stock of Sergeant’s Pet Care Products, Inc. (“Sergeant’s”), d/b/a Perrigo Animal Health, including any assets related to Perrigo Company plc’s animal health business (the “Perrigo Animal Health Acquisition”). In connection with the closing, we entered into a product development and asset purchase agreement with a third party for certain product formulations in development by the third party. The Company may make up to $20.6 million of payments over the course of the next several years contingent on achievement of certain development and regulatory approval milestones. Product development costs are expensed as incurred or as milestone payments become probable. There can be no assurance that these products will be approved by the U.S. Food and Drug Administration (“FDA”) on the anticipated schedule or at all. Consideration paid after FDA approval will be capitalized and amortized to cost of goods sold over the economic life of each product. The expenses paid prior to FDA approval will be included in General and Administrative expenses on the Consolidated Statements of Operations. No costs were incurred during the nine months ended September 30, 2020 or 2019.

Income taxes

The Company records a tax provision for the anticipated tax consequences of the reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. Based on the available objective evidence during the three and nine months ended September 30, 2020, the Company believes it is more likely than not that the tax benefits from our deferred tax assets, including net operating loss carry-forwards and other tax credits, may not be realized. Accordingly, the Company recorded a full valuation allowance against the tax benefits. We expect to maintain this full valuation allowance until sufficient positive evidence exists to support a reversal of, or decrease in, the valuation allowance.

Non-controlling interest

The non-controlling interests on the condensed consolidated statements of operations represents the portion of earnings or loss attributable to the economic interest in the Company’s subsidiary, Holdco, held by the non-controlling holders of Class B common stock and limited liability company interests in Holdco. Non-controlling interests on the condensed consolidated balance sheet represents the portion of net assets of the Company attributable to the non-controlling holders of Class B common stock and limited liability company interests in Holdco, based on the portion of the LLC Interests owned by holders of Class B common stock and limited liability company interests in Holdco. As of September 30, 2020 and December 31, 2019 the non-controlling interest was approximately 11.9% and 16.8%, respectively of ownership of LLC Interests.

Litigation

The Company is subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. If the likelihood of an adverse legal outcome is determined to be probable and the amount of loss is estimable, then a liability is accrued in accordance with accounting guidance for Contingencies. If the assessment indicates a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be

Table of Contents

estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, is disclosed. The Company consults with both internal and external legal counsel related to litigation.

Adopted Accounting Standard Updates

Effective January 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2016-13, "Financial Instruments - Credit Losses." This ASU requires an organization to measure all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable information. Organizations will now use forward-looking information to better estimate their credit losses. The Company adopted this ASU using a modified retrospective approach. Under this method of adoption, the Company determined that there was no cumulative-effect adjustment to beginning Retained earnings on the condensed consolidated balance sheet. Adoption of this standard did not impact the Company’s income before income taxes and had no impact on the condensed consolidated statement of cash flows.

In May 2020, the SEC issued Final Rule Release No. 33-10786, which amends the financial statement requirements for acquisitions and dispositions of businesses and related pro forma financial information required under SEC Regulation S-X, Rule 3-05. The final rule modifies the significance test required in SEC Regulation S-X, Rule 1-02(w) by raising the significance threshold for reporting dispositions of a business from 10% to 20% and by modifying the calculation of the investment and income tests. The Company has early adopted these modifications, which are effective for fiscal years starting after December 31, 2020 with early adoption permitted.

Upcoming Accounting Standard Updates

In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

Note 2 – Business Combination and Asset Acquisitions

Perrigo Animal Health Acquisition

On July 8, 2019, PetIQ, through Opco, completed the Perrigo Animal Health Acquisition. Sergeant’s is now an indirect wholly-owned subsidiary of the Company.

Table of Contents

The fair value of the consideration is summarized as follows:



$'s in 000's	Fair Value
Inventories	$	17,998
Property, plant and equipment		19,568
Other current assets		13,048
Other assets		9,680
Indefinite-lived intangible assets		23,040
Definite-lived intangible assets - 13 year weighted average life		14,480
Goodwill		105,838
Total assets		203,652

Liabilities assumed		19,259

Purchase price	$	184,393

Cash paid, net of cash acquired	$	(185,090)
Post-closing working capital adjustment		697

Fair value of total consideration transferred	$	(184,393)

The definite-lived intangibles primarily relate to trademarks, customer relationships, developed technology and know-how and in-process research and development intangibles. The $14.5 million represents the fair value and will be amortized over the estimated useful lives of the assets through June 2039. Amortization expense for these definite-lived intangible assets for the three and nine months ended September 30, 2020 was $0.6 million and $1.8 million, respectively.

The indefinite-lived intangibles primarily relate to trademarks and in-process research and development. We evaluate goodwill and indefinite-lived intangible assets for impairment on an annual basis and more frequently if an event occurs or circumstances change that would indicate impairment may exist.

Goodwill represents the future economic benefits that do not qualify for separate recognition and primarily includes the assembled workforce and other non-contractual relationships, as well as expected future synergies. Approximately $105.8 million of goodwill is expected to be deductible for tax purposes. Goodwill was allocated to the Products segment.

Capstar ® (nitenpyram) Acquisition

During the three months ended March 31, 2020, the Company executed an Asset Purchase Agreement (the “Purchase Agreement”) to acquire the U.S. rights to Capstar® and CapAction® and related assets (the “Capstar Acquisition”) from Elanco US Inc. (“Elanco”) for $95 million, plus the cost of certain outstanding finished goods inventory in saleable condition. The Capstar Acquisition was completed on July 31, 2020, using cash on hand as a result of the issuance of the Notes in May 2020.

The Capstar Acquisition was accounted for as an asset acquisition and certain transaction related costs of approximately $1.0 million were included in the cost of the acquired assets. The fair value assigned to trade names is typically based on the income approach using a relief from royalty methodology that assumes that the fair value of a trade name can be measured by estimating the cost of licensing and paying a royalty fee for the trade name that the owner of the trade name avoids. The estimated fair value of customer relationship was determined using an income approach, specifically a discounted cash flow analysis. The rate utilized to discount net cash flows to their present values was approximately 15% and was determined after consideration of the overall enterprise rate of return and the relative risk and importance

Table of Contents

of the assets to the generation of future cash flows.The fair value assigned to patents and processes typically uses the cost approach.The purchased assets are identified below:


$'s in 000's	Fair Value
Amortizable intangibles
Customer relationships	$	70,901
Patents and processes		9,895
Total amortizable intangibles		80,796
Non-amortizable intangibles
Trademarks and other		15,276
Total purchased intangible assets	$	96,072

The weighted average amortization period of the amortizable intangible assets is approximately 11.8 years.

Supplier Termination, Settlement and Asset Purchase Agreement:

The Company has a supplier who has alleged PetIQ has breached its supply agreement due to the acquisition of Perrigo Animal Health. During July 2020, the Company entered into a Termination, Settlement and Asset Purchase Agreement (“Agreement”). The Agreement called for PetIQ to pay $20.6 million, $2.6 million at signing and $1.0 million per quarter thereafter. The Agreement terminated the supply agreement that was previously in place, settled all outstanding claims and operations, and allowed PetIQ to purchase certain intellectual property related assets. The Company has estimated the fair value of the payment obligation as $17.5 million, and determined the fair value of the acquired assets to be $9.7 million. The assets acquired are included within the patents and processes intangible assets category and will be amortized over 10 years. The assets were valued using the relief from royalty method. The remainder of the obligation is considered to be a payment to settle the alleged breach of the supply agreement, the termination expense is included in general and administrative expenses on the condensed consolidated statement of operations for the nine months ended September 30, 2020. The obligation is considered debt and is included in debt on the condensed consolidated balance sheet. See Note 5 – “Debt” for additional information.

Note 3 – Property, Plant, and Equipment

Property, plant, and equipment consists of the following at:


$'s in 000's	September 30, 2020		December 31, 2019
Leasehold improvements	$	18,166	$	15,517
Equipment		25,247		23,138
Vehicles and accessories		6,768		6,007
Computer equipment and software		10,496		8,070
Buildings		10,114		10,050
Furniture and fixtures		2,426		1,836
Land		7,067		4,557
Construction in progress		8,755		3,392
		89,039		72,567
Less accumulated depreciation		(28,630)		(20,042)
Total property, plant, and equipment	$	60,409	$	52,525

Depreciation expense related to these assets was $3.0 million and $8.9 million for the three and nine months ended September 30, 2020 and $2.4 million and $5.6 million for the three and nine months ended September 30, 2019, respectively.

Table of Contents

Note 4 – Intangible Assets and Goodwill

Intangible assets consist of the following at:


$'s in 000's	Useful Lives	September 30, 2020		December 31, 2019
Amortizable intangibles
Certification	7 years	$	350	$	350
Customer relationships	12-20 years		160,111		89,232
Patents and processes	5-10 years		14,791		4,928
Brand names	5-15 years		24,688		15,019
Total amortizable intangibles			199,940		109,529
Less accumulated amortization			(21,333)		(13,058)
Total net amortizable intangibles			178,607		96,471
Non-amortizable intangibles
Trademarks and other			33,291		18,016
In-process research and development			5,469		5,469
Intangible assets, net of accumulated amortization		$	217,367	$	119,956

Certain intangible assets are denominated in currencies other than the U.S. Dollar; therefore, their gross and net carrying values are subject to foreign currency movements. Amortization expense for the three months ended September 30, 2020 and 2019 was $3.8 million and $1.8 million, respectively, and $8.3 million and $4.4 million for the nine months ended September 30, 2020 and 2019, respectively.

The in-process research and development (“IPRD”), intangible assets represent the value assigned to acquired R&D projects that principally represent rights to develop and sell a product that the Company has acquired which have not yet been completed or approved. The IPRD acquired as part of the Perrigo Animal Health Acquisition is accounted for as an indefinite-lived asset until the product is available for sale and regulatory approval is obtained, or abandonment of the associated research and development efforts. If the research and development efforts are successfully completed, the IPRD would be amortized over its then estimated useful life. The fair value of the IPRD was estimated using the multi-period excess earnings income method. The projected cash flows estimates for the future products were based on certain key assumptions including estimates of future revenues and expenses, taking into account the stage of development at the acquisition date and the resources needed to complete development.

Estimated future amortization expense for each of the following years is as follows:


Years ending December 31, ($'s in 000's)
Remainder of 2020	$	4,552
2021		18,838
2022		18,627
2023		17,873
2024		15,496
Thereafter		103,221

Table of Contents

The following is a summary of the changes in the carrying value of goodwill for the period from January 1, 2019 to September 30, 2020:


	Reporting Unit
($'s in 000's)	Products		Services		Total
Goodwill as of January 1, 2019		77,765		47,264		125,029
Foreign currency translation		178		—		178
Acquisitions		105,838		—		105,838
Goodwill as of December 31, 2019		183,781		47,264		231,045
Foreign currency translation		(173)		—		(173)
Goodwill as of September 30, 2020	$	183,608	$	47,264	$	230,872

Note 5 – Debt

Convertible Notes

On May 19, 2020, the Company issued $143.8 million in aggregate principal amount of 4.00% Convertible Senior Notes due 2026 pursuant to the indenture (the “Indenture”), dated as of May 19, 2020. The total net proceeds from the Notes offering, after deducting debt issuance costs paid or payable by us, was $137.9 million. The Notes accrue interest at a rate of 4.00% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020. The Notes will mature on June 1, 2026, unless earlier repurchased, redeemed or converted. Before January 15, 2026, holders will have the right to convert their Notes only upon the occurrence of certain events. From and after January 15, 2026, holders may convert their Notes at any time at their election until the close of business on the scheduled trading day immediately before the maturity date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock, or a combination of cash and shares of its Class A common stock, at its election. The initial conversion rate is 33.7268 shares of Class A common stock per $1,000 principal amount of Notes. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.

The Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 1, 2023 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company’s Class A common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. In addition, calling any Notes will constitute a Make-Whole Fundamental Change with respect to such Notes, which will result in an increase to the conversion rate if such Notes are converted after they are called for redemption.

If certain corporate events that constitute a “Fundamental Change” (as defined in the Indenture) occur, then noteholders may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company’s Class A common stock.

The Notes are the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. The Notes contain customary events of default.

Table of Contents

In accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated using a discount rate of 13%, which was determined by measuring the fair value of a similar debt instrument that does not have an associated convertible feature. The amount of the equity component representing the conversion option was $53.3 million and was determined by deducting the fair value of the liability component from the par value of the Notes. The excess of the principal amount of the liability component over its carrying amount, or the debt discount, is amortized to interest expense at an annual effective interest rate over the contractual terms of the Notes.

The fair value of the Notes was $195.4 million as of September 30, 2020. The estimated fair value of the Notes is based on market rates and the closing trading price of the Convertible Notes as of September 30, 2020 and is classified as Level 2 in the fair value hierarchy. As of September 30, the if-converted value of the Notes did not exceed the principal amount.

The net carrying amount of the liability component of the Notes was as follows:


($'s in 000's)	September 30, 2020
Par value of the Notes	$	143,750
Unamortized debt discount		(51,085)
Unamortized debt issuance costs		(3,550)
Net carrying amount	$	89,115

The net carrying amount of the equity component of the Notes was as follows:


($'s in 000's)	September 30, 2020
Proceeds allocated to the conversion option	$	53,285
Deferred tax affect		(8,134)
Issuance costs		(2,181)
Net carrying amount	$	42,970

The following table sets forth the interest expense recognized related to the Notes:


	For the Three Months Ended		For the Nine Months Ended
	September 30, 2020		September 30, 2020
($'s in 000's)
Contractual interest expense	$	1,438	$	2,108
Amortization of debt issuance costs		1,510		2,199
Amortization of debt discount		105		153
Total	$	3,053	$	4,460
Effective interest rate of the liability component		13.0%		13.0%

Capped Call Transactions

On May 14, 2020 and May 19, 2020, the Company entered into capped call transactions (the “Capped Call Transactions”) with two counterparties (the “Option Counterparties”). The Capped Call Transactions cover, subject to anti-dilution adjustments substantially similar to the Notes, the underlying shares of Class A common stock and are intended to reduce, subject to a limit, the potential dilution with respect to the Class A common stock upon conversion of the Notes. The cap price of the Capped Call Transactions is $41.51 per share of Class A common stock, and is subject to certain adjustments under the terms of the Capped Call Transactions.

The Company paid approximately $14.8 million for the Capped Call Transactions, which was recorded as additional paid-in capital, using a portion of the gross proceeds from the sale of the Notes. The capped call is expected to be tax deductible as the Company elected to integrate the capped call into the Notes for tax purposes. The tax effect on the equity component of the Convertible Notes of $8.1 million was recorded through additional paid-in capital. The Company has recorded a full valuation allowance against its deferred tax assets as of September 30, 2020, as a result, the

Table of Contents

$8.1 million deferred tax liability associated with the Capped Call Transactions will be offset by a reduction to the valuation allowance adjustment through continuing operations.

A&R Credit Agreement

The Company amended the existing revolving credit agreement of Opco and each of its domestic wholly-owned subsidiaries (the “Amended Revolving Credit Agreement”) on July 8, 2019. The Amended Revolving Credit Agreement provides for a secured revolving credit facility of $125 million that matures on July 8, 2024. The borrowers under the Amended Revolving Credit Facility incur fees between 0.375% and 0.50% as unused facility fees, dependent on the aggregate amount borrowed. On May 14, 2020, the Company amended the Amended Revolving Credit Agreement to allow for the Notes described above. Additionally the amendment instituted a Eurodollar floor of 1% to the agreement.

All obligations under the Amended Revolving Credit Agreement are unconditionally guaranteed by HoldCo and, subject to certain exceptions, each of its material current and future domestic wholly-owned subsidiaries. All obligations under the Amended Revolving Credit Agreement, and the guarantees of those obligations, are secured by substantially all of the assets of each borrower and guarantor under the Amended Revolving Credit Agreement, subject to certain exceptions.

The Amended Revolving Credit Agreement contains a number of covenants that, among other things, restrict the ability of the borrowers and guarantors thereunder to (subject to certain exceptions): (i) make investments, loans or advances; (ii) incur additional indebtedness; (iii) create liens on assets; (iv) engage in mergers or consolidations and/or sell assets; (v) pay dividends and distributions or repurchase our equity interests; (vi) repay subordinated indebtedness; (vii) make certain acquisitions; and (viii) other restrictions typical for a credit agreement of this type. As of September 30, 2020, the borrowers and guarantors thereunder were in compliance with these covenants. Although the Company currently expects continued compliance with debt covenants, the impact COVID-19 may negatively affect the Company’s ability to comply with these covenants. The Amended Revolving Credit Agreement also contains certain customary affirmative covenants and events of default (including change of control). In addition, the Amended Revolving Credit Agreement contains a minimum fixed charge coverage ratio covenant which is tested if availability under the Amended Revolving Credit Agreement falls below a certain level. As of September 30, 2020, the borrower and guarantors thereunder were in compliance with these covenants.

As of September 30, 2020, $15.0 million was outstanding under the Amended Revolving Credit Agreement. The weighted average interest rate on the Amended Revolving Credit Agreement was 2.3% at September 30, 2020.

A&R Term Loan Credit Agreement

The Company amended and restated the existing term loan credit agreement of Opco (the “A&R Term Loan Credit Agreement”) on July 8, 2019. The $220.0 million A&R Term Loan Credit Agreement has an interest rate equal to the Eurodollar rate plus 4.50%. The A&R Term Loan Credit Agreement calls for 1% of the original loan balance to be paid annually via equal quarterly payments, with the balance of the loan due on the sixth anniversary of the agreement.

All obligations under the A&R Term Loan Credit Agreement are unconditionally guaranteed by PetIQ Holdings, LLC and each of its domestic wholly-owned subsidiaries and, subject to certain exceptions, each of its material current and future domestic wholly-owned subsidiaries. All obligations under the A&R Term Loan Credit Agreement, and the guarantees of those obligations, are secured by substantially all of the assets of PetIQ, LLC and each guarantor under the A&R Term Loan Credit Agreement, subject to certain exceptions.

The A&R Term Loan Credit Agreement contains a number of covenants that, among other things, restrict the ability of the borrower and guarantors thereunder to (subject to certain exceptions): (i) make investments, loans or advances; (ii) incur additional indebtedness; (iii) create liens on assets; (iv) engage in mergers or consolidations and/or sell assets; (v) pay dividends and distributions or repurchase our equity interests; (vi) repay subordinated indebtedness; (vii) make certain acquisitions; and (viii) other restrictions typical for a credit agreement of this type. The A&R Term Loan Credit Agreement also contains certain customary affirmative covenants and events of default (including change of control). In addition, the A&R Term Loan Credit Agreement includes a maintenance covenant that requires compliance with a maximum first lien net leverage ratio. The availability of certain baskets and the ability to enter into certain transactions (including our ability

Table of Contents

to pay dividends) may also be subject to compliance with secured leverage ratios. As of September 30, 2020, the borrower and guarantors thereunder were in compliance with these covenants.

General Other Debt

The Company entered into a mortgage with a local bank to finance $1.9 million of the purchase price of a commercial building in Eagle, Idaho, in July 2017. The mortgage bears interest at a fixed rate of 4.35% and utilizes a 25 year amortization schedule with a 10 year balloon payment of the balance due at that time.

In July 2020, the Company entered into the Agreement. See Note 2 – “Business Combinations and Asset Acquisitions”. The Agreement called for PetIQ to pay $20.6 million, $2.6 million at signing and $1.0 million per quarter thereafter with no interest. The Company discounted the payment stream using a market interest rate of 8.3%, resulting in an obligation of $17.5 million.

In connection with the VIP Acquisition, the Company entered into a guarantee note and the Contingent Notes (together the “Notes Payable – VIP Acquisition”), which have a collective balance of $27.5 million and require quarterly interest payments of 6.75% with the balance payable July 17, 2023. The following represents the Company’s long-term debt as of:


$'s in 000's	September 30, 2020		December 31, 2019
Convertible Notes	$	143,750	$	—
Term loans		217,800		220,000
Revolving credit facility		15,000		10,000
Notes Payable - VIP Acquisition		27,500		27,500
Other Debt		16,974		1,812
Net discount on debt and deferred financing fees		(59,279)		(5,688)
	$	361,745	$	253,624
Less current maturities of long-term debt		(6,250)		(2,248)
Total long-term debt	$	355,495	$	251,376

Future maturities of long-term debt, excluding the discount on debt and deferred financing fees, as of September 30, 2020, are as follows:


($'s in 000's)
Remainder of 2020	$	1,562
2021		6,250
2022		6,252
2023		33,755
2024		6,257
Thereafter		366,948

The Company incurred debt issuance costs of $0.3 million and $0.6 million related to the A&R Credit Agreement during the three and nine months ended September 30, 2020, respectively. The Company incurred debt issuance costs of $0.7 million related to the A&R Credit Agreement and $4.7 million related to the Term Loan during the three and nine months ended September 30, 2019.

The Company incurred debt issuance costs of $5.9 million in May 2020 in connection with the Notes. In accordance with FASB ASC 470, Debt, these costs were allocated to debt and equity components in proportion to the allocation of proceeds. $2.2 million of issuance costs were recorded as additional paid-in capital and such amounts are not subject to amortization. The remaining issuance costs of $3.7 million are recorded as debt issuance costs in the net carrying value of the Notes. The debt issuance costs are amortized on an effective interest basis over the term of the Notes and is

Table of Contents

included in interest expense, net on the condensed consolidated statements of operations. Future amortization of our debt discount and debt issuance costs for the the term of the Convertible Notes is as follows:


($'s in 000's)	Debt Discounts		Debt Issuance Costs
Remainder of 2020	$	1,559	$	108
2021		6,761		460
2022		7,684		522
2023		8,733		594
2024		9,925		675
Thereafter		16,423		1,191

Note 6 – Leases

The Company leases certain real estate for commercial, production, and retail purposes, as well as equipment from third parties. Lease expiration dates are between 2020 and 2026. A portion of leases are denominated in foreign currencies.

For both operating and finance leases, the Company recognizes a right-of-use asset, which represents the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of our obligation to make payments arising over the lease term.

We elected the short-term lease exemption for all leases that qualify. This means leases having an initial term of twelve months or less are not recorded on the balance sheet and the related lease expense is recognized on a straight-line basis over the term of the lease.

The Company's leases may include options to extend or terminate the lease. Renewal options generally range from one to ten years and the options to extend are included in the lease term when it is reasonably certain that we will exercise that option. Some leases have variable payments, however, because they are not based on an index or rate, they are not included in the ROU assets and liabilities. Variable payments for real estate leases primarily relate to percentage of revenue, common area maintenance, insurance, taxes and utilities. Variable payments for equipment, vehicles, and leases within supply agreements primarily relate to usage, repairs, and maintenance. As the implicit rate is not readily determinable for most of the Company's leases, the Company applies a portfolio approach using an estimated incremental borrowing rate, giving consideration to company specific information and publicly available interest rates for instruments with similar characteristics, to determine the initial present value of lease payments over the lease terms.


	For the Three Months Ended				For the Nine Months Ended
$'s in 000's	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Finance lease cost
Amortization of right-of-use assets	$	409	$	337	$	1,191	$	1,038
Interest on lease liabilities		11		126		170		235
Operating lease cost		1,316		3,293		4,426		5,164
Variable lease cost⁽¹⁾		530		208		783		395
Short-term lease cost		12		29		31		48
Sublease income		(226)		—		(679)		—
Total lease cost	$	2,052	$	3,993	$	5,922	$	6,880

(1)

Variable lease cost primarily relates to percentage rent, common area maintenance, property taxes and insurance on leased real estate.

Table of Contents

Other information related to leases was as follows as of:


	September 30, 2020	December 31, 2019
Weighted-average remaining lease term (years)
Operating leases	4.52	5.15
Finance leases	2.45	2.73
Weighted-average discount rate
Operating leases	5.3%	5.3%
Finance leases	5.8%	5.7%

Annual future commitments under non-cancelable leases as of September 30, 2020, consist of the following:


	Lease Obligations
$'s in 000's	Operating Leases		Finance Leases
Remainder of 2020	$	1,503	$	419
2021		5,491		1,560
2022		5,182		1,394
2023		4,368		1,400
2024		2,846		332
Thereafter		3,274		20
Total minimum future obligations	$	22,664	$	5,125
Less interest		(2,608)		(406)
Present value of net future minimum obligations		20,056		4,719
Less current lease obligations		(4,718)		(1,467)
Long-term lease obligations	$	15,338	$	3,252

Supplemental cash flow information:



	Nine Months Ended		Nine Months Ended
$'s in 000's	September 30, 2020		September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$	170	$	235
Operating cash flows from operating leases		4,334		3,110
Financing cash flows from finance leases		1,252		1,103
(Noncash) right-of-use assets obtained in exchange for lease obligations
Operating leases		3,153		4,648
Finance leases		993		535

Note 7 – Income Tax

As a result of the Company’s initial public offering and related reorganization transactions completed in July 2017, the Company held a majority of the economic interest in Holdco and consolidates the financial position and results of Holdco. The remaining ownership of Holdco not held by the Company is considered a non-controlling interest. Holdco is treated as a partnership for income tax reporting. Holdco’s members, including the Company, are liable for federal, state, and local income taxes based on their share of Holdco’s taxable income.

Our effective tax rate (ETR) from continuing operations was (468.0)% and (305.1)% for the three and nine months ended September 30, 2020, respectively, and 12.9% and (16.3)% for the three and nine months ended September 30, 2019, respectively, including discrete items. Income tax expense for nine months ended September 30, 2020 and 2019 was different than the U.S federal statutory income tax rate of 21% primarily due to the effect of state taxes, foreign

Table of Contents

GILTI income inclusion, various permanent tax differences, the non-controlling interest income that is not taxable and the recognition of a valuation allowance during the three and nine months ended September 30, 2020.

The Company has assessed the realizability of the net deferred tax assets as of September 30, 2020 and in that analysis has considered the relevant positive and negative evidence available to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income to realize its deferred tax assets. The Company believes it is more likely than not that the benefit from recorded deferred tax assets will not be realized. The Company has recorded a valuation allowance for deferred tax assets of $61.2 million and $0.1 million as of September 30, 2020 and December 31, 2019, respectively. In future periods, if we conclude we have future taxable income sufficient to recognize the deferred tax assets, we may reduce or eliminate the valuation allowance.

HoldCo makes cash distributions to members to pay taxes attributable to their allocable share of income earned. In the three and nine months ended September 30, 2020, the Company made cash distributions of $0 and $0.05 million, respectively. In the three and nine months ended September 30, 2019, the Company made cash distributions of $0.3 million and $1.6 million, respectively. Additionally, HoldCo accrues for distributions required to be made related to estimated income taxes. During the three and nine months ended September 30, 2020, the Company relieved previously accrued distributions of $(0.8) million and $(0.4) million, respectively, and during the three and nine months ended September 30, 2019, the Company relieved previously accrued distributions by $(1.0) million and accrued $0.1 million, respectively.

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property, and the creation of certain refundable employee retention credits. The Company will benefit from the Employee Retention Credits and the payroll tax deferral.

Note 8 – Earnings per Share

Basic and Diluted (Loss) Earnings per Share

Basic earnings (loss) per share of Class A common stock is computed by dividing net (loss) income available to PetIQ by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted (loss) earnings per share of Class A common stock is computed by dividing net (loss) income available to PetIQ by the weighted-average number of shares of Class A common stock outstanding adjusted to give effect to potentially dilutive securities. We use the ‘if-converted’ method for calculating any potential dilutive effect of the Notes on diluted earnings per share, subject to meeting the criteria for using the treasury stock method in future periods.

Table of Contents

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per share of Class A common stock:


	Three months ended September 30,				Nine months ended September 30,
(in 000's, except for per share amounts)		2020	2019			2020	2019
Numerator:
Net loss	$	(64,529)	$	(8,796)	$	(69,122)	$	(552)
Less: net loss attributable to non-controlling interests		(1,468)		(2,906)		(2,067)		(88)
Net loss attributable to PetIQ, Inc. — basic and diluted		(63,061)		(5,890)		(67,055)		(464)
Denominator:
Weighted-average shares of Class A common stock outstanding -- basic		24,935		22,974		24,365		22,387
Dilutive effects of stock options that are convertible into Class A common stock		—		—		—		—
Dilutive effect of RSUs		—		—		—		—
Dilutive effect for conversion of Notes		—		—		—		—
Weighted-average shares of Class A common stock outstanding -- diluted		24,935		22,974		24,365		22,387

Loss per share of Class A common stock — basic	$	(2.53)	$	(0.26)	$	(2.75)	$	(0.02)
Loss per share of Class A common stock — diluted	$	(2.53)	$	(0.26)	$	(2.75)	$	(0.02)

Shares of the Company’s Class B common stock do not share in the earnings or losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share of Class B common stock under the two-class method has not been presented.

For the three and nine months ended September 30, 2020 and 2019, all shares of the Company’s Class B common stock have not been included in the diluted earnings per share calculation as they have been determined to be anti-dilutive under the if-converted method, respectively.

Additionally, all stock options and restricted stock units and convertible Notes have not been included in the diluted earnings per share calculation for the three and nine months ended September 30, 2020 and 2019, as they have been determined to be anti-dilutive under the treasury stock method.

Note 9 – Stock Based Compensation

PetIQ, Inc. Omnibus Incentive Plan

The PetIQ, Inc. Omnibus Incentive Plan, as amended (the “Plan”) provides for the grant of various equity-based incentive awards to directors of the Company, employees, and consultants. The types of equity-based awards that may be granted under the Plan include: stock options, stock appreciation rights (SARs), restricted stock, restricted stock units (RSUs), and other stock-based awards. The Company has 3,914 thousand authorized shares under the Plan. As of September 30, 2020, 1,280 thousand shares were available for issuance under the Plan. All awards issued under the Plan may only be settled in shares of Class A common stock.

PetIQ, Inc. 2018 Inducement and Retention Stock Plan for CVC Employees

The PetIQ, Inc. 2018 Inducement and Retention Stock Plan for CVC Employees (the “Inducement Plan”) provided for the grant of stock options to employees hired in connection with the VIP Acquisition as employment inducement awards pursuant to NASDAQ Listing Rule 5635(c)(4). The Inducement Plan reserved 800 thousand shares of Class A Common Stock of the Company. As of September 30, 2020, no shares were available for issuance under the Inducement Plan. All awards issued under the Plan may only be settled in shares of Class A common stock.

Stock Options

The Company awards stock options to certain employees and directors under the Plan and previously issued stock options under the Inducement Plan, which are subject to time-based vesting conditions, typically 25% on each

Table of Contents

anniversary of the grant date until fully vested. Upon a termination of service relationship by the Company, all unvested options will be forfeited and the shares of common stock underlying such awards will become available for issuance under the Plan. The maximum contractual term for stock options is 10 years.

The fair value of these equity awards is amortized to equity based compensation expense over the vesting period, which totaled $1.3 million and $4.9 million for the three and nine months ended September 30, 2020, respectively, and $1.4 million and $4.0 million for the three and nine months ended September 30, 2019. All stock based compensation expense is included in general and administrative expenses based on the role of recipients. The fair value of the stock option awards was determined on the grant dates using the Black-Scholes valuation model based on the following weighted-average assumptions for the periods ended September 30, 2020 and 2019:


	September 30, 2020			September 30, 2019
Expected term (years) ⁽¹⁾		6.25			6.25
Expected volatility ⁽²⁾		33.91	%		35.00	%
Risk-free interest rate ⁽³⁾		0.37	%		2.74	%
Dividend yield ⁽⁴⁾		0.00	%		0.00	%

(1)

The Company utilized the simplified method to determine the expected term of the stock options since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.

(2)

The expected volatility assumption was calculated based on a peer group analysis of stock price volatility with a look back period consistent with the expected option term.

(3)

The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds to the expected term of the stock options.

(4)

The Company has not paid and does not anticipate paying a cash dividend on our common stock.

The weighted average grant date fair value of stock options granted during the period ended September 30, 2020 was $6.70 per option. At September 30, 2020, total unrecognized compensation cost related to unvested stock options was $10.1 million and is expected to be recognized over a weighted-average period of 2.4 years.


							Weighted
							Average
			Weighted		Aggregate		Remaining
	Stock		Average		Intrinsic		Contractual
	Options		Exercise		Value		Life
	(in 000's)		Price		(in 000's)		(years)
Outstanding at December 31, 2019		2,072	$	24.63	$	6,266		8.0
Granted		505		20.22
Exercised		(345)		23.76
Forfeited		(89)		21.44
Outstanding at September 30, 2020		2,143	$	23.86	$	20,332		7.6
Options exercisable at September 30, 2020		752

Restricted Stock Units

The Company awards RSUs to certain employees and directors under the Plan, which are subject to time-based vesting conditions. Upon a termination of service relationship by the Company, all unvested RSUs will be forfeited and the shares of common stock underlying such awards will become available for issuance under the Plan. The fair value of RSUs are measured based on the closing fair market value of the Company’s common stock on the date of grant. At September 30, 2020, total unrecognized compensation cost related to unvested RSUs was $6.9 million and is expected to vest over a weighted average 3.0 years.

The fair value of these equity awards is amortized to equity based compensation expense over the vesting period, which totaled $0.5 million and $1.7 million for the three and nine months ended September 30, 2020 and $0.3 million and $0.8

Table of Contents

million for the three and nine months ended September 30, 2019. All stock based compensation expense is included in general and administrative expenses based on the role of recipients.

The following table summarizes the activity of the Company’s RSUs for the period ended September 30, 2020.


			Weighted
	Number of		Average
	Shares		Grant Date
	(in 000's)		Fair Value
Outstanding at December 31, 2019		133	$	28.85
Granted		271		20.73
Settled		(45)		26.54
Forfeited		(10)		22.27
Nonvested RSUs at September 30, 2020		349	$	23.03

Note 10 – Stockholders’ Equity

Exchanges

During the nine months ended September 30, 2020 holders of Class B common stock and LLC Interests exercised exchange rights and exchanged 1,332 thousand Class B common shares and corresponding LLC Interests for newly issued Class A Common Stock. The LLC Agreement generally allows for exchanges on the last day of each calendar month.

Note 11 – Non-Controlling Interests

The following table presents the outstanding LLC Interests and changes in LLC Interests for the periods presented.


	LLC Interests held					% of Total
		LLC				LLC
$'s in 000's	Owners		PetIQ, Inc.		Total	Owners	PetIQ, Inc.
As of December 31, 2019		4,752		23,554	28,306	16.8%	83.2%
Stock based compensation adjustments		—		370	370
Exchange transactions		(1,332)		1,332	—
As of September 30, 2020		3,420		25,256	28,676	11.9%	88.1%

Note that certain figures shown in the table above may not recalculate due to rounding.

For the three and nine months ended September 30, 2020 the Company owned a weighted average of 87.2% and 85.7% of Holdco, respectively.

Note 12 – Customer Concentration

The Company has significant exposure to customer concentration. During the three and nine months ended September 30, 2020, two customers individually accounted for more than 10% of sales, comprising 42% and 42% of net sales, respectively for such periods. During the three and nine months ended September 30, 2019 one and two customers individually accounted for more than 10% of sales, together comprising 23% and 35% of net sales in both such periods.

At September 30, 2020 one Products segment customer individually accounted for more than 10% of outstanding trade receivables, and accounted for 44% of outstanding trade receivables, net. At December 31, 2019 two Products segment customers individually accounted for more than 10% of outstanding trade receivables, and accounted for 61% of outstanding trade receivables, net.

Table of Contents

Note 13 – Commitments and Contingencies

Litigation Contingencies

On April 4, 2018, Med Vets, Inc. and Bay Medical Solutions Inc. (collectively “Plaintiffs”) filed suit in the United States District Court for the Northern District of California against PetIQ and VIP Petcare Holdings, Inc. for alleged unlawful merger and other antitrust violations. On June 29, 2020, the 9^th Circuit Court of Appeals issued an opinion affirming the dismissal of Med Vets’ merger challenge. On July 13, 2020, the Plaintiffs filed for an en banc hearing in the 9^th Circuit Court of Appeals which was unanimously denied on August 7, 2020. As no impact to the Company is considered probable or estimable, no litigation reserve has been accrued.

The Company records a liability when a particular contingency is probable and estimable and provides disclosure for contingencies that are at least reasonably possible of resulting in a loss including an estimate which we currently cannot make. The Company has not accrued for any contingency at September 30, 2020 and December 31, 2019 as the Company does not consider any contingency to be probable or estimable. The Company expenses legal costs as incurred within general and administrative expenses on the consolidated condensed statements of operations.

Note 14 – Segments

The Company has two operating segments: Products and Services. The Products segment consists of the Company’s manufacturing and distribution business. The Services segment consists of the Company’s veterinary services, and related product sales, provided by the Company directly to consumers.

The segments are based on the discrete financial information reviewed by the Chief Operating Decision Maker (“CODM”) to make resource allocation decisions and to evaluate performance. We measure and evaluate our reportable segments based on net sales and segment Adjusted EBITDA. We exclude from our segments certain corporate costs and expenses, such as accounting, legal, human resources, information technology and corporate headquarters expenses as our corporate functions do not meet the definition of a segment as defined in the accounting guidance related to segment reporting.

Financial information relating to the Company’s operating segments for the three months ended:


$'s in 000's					Unallocated
September 30, 2020	Products		Services		Corporate		Consolidated
Net Sales	$	150,063	$	12,020	$	—	$	162,083
Adjusted EBITDA		26,318		(223)		(14,088)		12,007
Depreciation expense		1,201		937		892		3,030
Capital expenditures		5,072		2,193		122		7,387


$'s in 000's					Unallocated
September 30, 2019	Products		Services		Corporate		Consolidated
Net Sales	$	161,534	$	24,491	$	—	$	186,025
Adjusted EBITDA		20,506		7,048		(8,296)		19,258
Depreciation expense		1,228		547		629		2,404
Capital expenditures	$	188	$	2,984	$	210	$	3,382

Financial information relating to the Company’s operating segments for the nine months ended:


$'s in 000's					Unallocated
September 30, 2020	Products		Services		Corporate		Consolidated
Net Sales	$	580,650	$	35,193	$	—	$	615,843
Adjusted EBITDA		92,448		2,878		(40,555)		54,771
Depreciation expense		3,685		2,674		2,527		8,886
Capital expenditures		10,337		5,966		1,508		17,811

Table of Contents


$'s in 000's					Unallocated
September 30, 2019	Products		Services		Corporate		Consolidated
Net Sales	$	482,224	$	72,871	$	—	$	555,095
Adjusted EBITDA		56,030		18,147		(23,217)		50,960
Depreciation expense		2,134		1,591		1,862		5,587
Capital expenditures		1,462		3,290		376		5,128

The following table reconciles Segment Adjusted EBITDA to Net loss for the periods presented.


	For the three months ended				For the nine months ended
$'s in 000's	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Adjusted EBITDA:
Product	$	26,318	$	20,506	$	92,448	$	56,030
Services		(223)		7,048		2,878		18,147
Unallocated Corporate		(14,088)		(8,296)		(40,555)		(23,217)
Total Consolidated		12,007		19,258		54,771		50,960
Adjustments:
Depreciation		(3,030)		(2,404)		(8,886)		(5,587)
Amortization		(3,821)		(1,807)		(8,313)		(4,364)
Interest		(7,829)		(5,742)		(18,500)		(9,921)
Acquisition costs⁽¹⁾		(1,083)		(1,960)		(1,815)		(5,425)
Stock based compensation expense		(2,147)		(1,601)		(6,549)		(4,747)
Integration costs and costs of discontinued clinics⁽²⁾		(307)		(1,166)		(9,611)		(2,308)
SKU Rationalization⁽³⁾		—		(6,482)		—		(6,482)
Fair value adjustment of contingent note⁽⁴⁾		—		(2,310)		—		(3,090)
Purchase accounting adjustment to inventory		—		(2,403)		—		(2,403)
Non same-store revenue⁽⁵⁾		2,884		2,583		6,119		6,254
Non same-store costs⁽⁵⁾		(5,378)		(5,394)		(15,476)		(12,690)
Clinic launch expenses⁽⁶⁾		(767)		(672)		(2,046)		(672)
Litigation expenses		(290)		—		(723)		—
COVID-19 related costs⁽⁷⁾		(1,600)		—		(6,033)		—
Pretax net loss	$	(11,361)	$	(10,100)	$	(17,062)	$	(475)
Income tax benefit (expense)		(53,168)		1,304		(52,060)		(77)
Net loss	$	(64,529)	$	(8,796)	$	(69,122)	$	(552)

(1)

Acquisition costs include legal, accounting, banking, consulting, diligence, and other out-of-pocket costs related to completed and contemplated acquisitions.

(2)

Integration costs and costs of discontinued clinics represent costs related to integrating the acquired businesses, such as personnel costs like severance and signing bonuses, consulting work, contract termination, and IT conversion costs. These costs are primarily in the Products segment and the corporate segment for personnel costs, legal and consulting expenses, and IT costs.

(3)

Table of Contents

and brands acquired as part of the Perrigo Animal Health Acquisition. All costs are included in the Products segment gross margin.

(4)

Fair value adjustment on the contingent note represents the non cash adjustment to mark the 2019 Contingent Note to fair value.

(5)

Non same-store revenue and costs relate to our Services segment and are from wellness centers, host partners, and regions with less than six full trailing quarters of operating results.

(6)

Clinic launch expenses relate to our Services segment and represent the nonrecurring costs to open new veterinary wellness centers, primarily employee costs, training, marketing, and rent prior to opening for business.

(7)

Costs related to maintaining service segment infrastructure, staffing, and overhead related clinics and wellness centers closed due to COVID-19 related health and safety initiatives. Product segment and unallocated corporate costs related to incremental wages paid to essential workers and sanitation costs due to COVID.

Supplemental geographic disclosures are below.


		Nine months ended September 30, 2020
$'s in 000's		U.S.		Foreign		Total
Product sales	$	576,756	$	3,894	$	580,650
Service revenue		35,193		—		35,193
Total net sales	$	611,949	$	3,894	$	615,843


		Nine months ended September 30, 2019
$'s in 000's		U.S.		Foreign		Total
Product sales	$	478,979	$	3,245	$	482,224
Service revenue		72,871		—		72,871
Total net sales	$	551,850	$	3,245	$	555,095


		Three months ended September 30, 2020
$'s in 000's		U.S.		Foreign		Total
Product sales	$	148,424	$	1,639	$	150,063
Service revenue		12,020		—		12,020
Total net sales	$	160,444	$	1,639	$	162,083


		Three months ended September 30, 2019
$'s in 000's		U.S.		Foreign		Total
Product sales	$	159,922	$	1,612	$	161,534
Service revenue		24,491		—		24,491
Total net sales	$	184,413	$	1,612	$	186,025

Property, plant, and equipment by geographic location is below.


	September 30, 2020		December 31, 2019
United States	$	59,116	$	51,397
Europe		1,293		1,128
Total	$	60,409	$	52,525

Table of Contents

Note 15 – Related Parties

As discussed in Note 7– “Income Taxes”, the Company has accrued tax distributions that are payable to Continuing LLC Owners to facilitate the Continuing LLC Owners periodic estimated tax obligations. At September 30, 2020 and December 31, 2019, the Company had paid $0.04 million in advance on required tax distributions and accrued $0.4 million, respectively, for estimated tax distributions, which are included in accounts payable on the consolidated balance sheets.

As discussed in Note 5– “Debt,” the Company has notes payable to the sellers of VIP, who are significant shareholders of the Company, of $27.5 million in aggregate as of September 30, 2020 and December 31, 2019. The Company had $0.5 million in accrued interest on these notes as of September 30, 2020 and no accrued interest on these notes as of December 31, 2019. The Company paid $0.5 million in the three months ended September 30, 2020 and paid $1.2 million of interest in the nine months ended September 30, 2020. The Company paid no interest in the three months ended September 30, 2019, but paid $0.7 million in the nine months ended September 30, 2019.

The Company leases office and warehouse space from a company under common control of the sellers of VIP, commencing on January 17, 2018. The Company incurred rent expenses of $0.1 million and $0.3 million in the three and nine months ended September 30, 2020 and $0.1 million and $0.3 million in the three and nine months ended September 30, 2019, respectively.

Chris Christensen, the brother of CEO, McCord Christensen, acts as the Company’s agent at Moreton Insurance (“Moreton”), which acts as a broker for a number of the Company’s insurance policies. The Company’s premium expense, paid to Moreton and subsequently transferred to insurance providers, was $0.7 million and $1.0 million for the three and nine months ended September 30, 2020 and $0.6 million and $0.7 million for the three and nine months ended September 30, 2019. Mr. Chris Christensen was paid a commission of approximately $32 thousand and $50 thousand for the three and nine months ended September 30, 2020, respectively, and $28 thousand and $35 thousand for the three and nine months ended September 30, 2019, respectively, for the sale of such insurance policies to the Company.

In April 2020, the Company purchased a parcel of land for $2.5 million. The broker for the Company was Colliers International, and the agent was Mike Christensen, the brother of CEO McCord Christensen. Total commission paid to Colliers was approximately $75 thousand.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following is a discussion of our results of operations and current financial condition. This should be read in conjunction with the accompanying unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements for the year ended December 31, 2019 and related notes included in the annual report for PetIQ, Inc., filed with the Securities and Exchange Commission (the “SEC”) on Form 10-K for the year ended December 31, 2019. This discussion contains forward-looking statements that reflect our plans, estimates, and beliefs and involve numerous risks and uncertainties. Actual results may differ materially from those contained in any forward-looking statements. See “Cautionary Note Regarding Forward-Looking Statements.”

Business Overview

PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. We engage with customers through more than 60,000 points of distribution across retail and e-commerce channels with our branded distributed medications, which is further supported by our own world-class medication manufacturing facility in Omaha, Nebraska. Our national service platform, VIP Petcare, operates in over 3,400 retail partner locations in 41 states, providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.

We have two reporting segments: (i) Products; and (ii) Services. The Products segment consists of our manufacturing and distribution business. The Services segments consists of our veterinary services, and related product sales, provided by the Company directly to consumers.

We are the sole managing member of PetIQ Holdings, LLC ("Holdco"), a Delaware limited liability company, which is the sole member of PetIQ, LLC ("Opco") and, through Holdco, operate and control all of the business and affairs of Opco.

Table of Contents

Coronavirus Disease (COVID-19) Considerations

On March 11, 2020, the World Health Organization formally declared the Novel Coronavirus (“COVID-19”) outbreak to be a pandemic. The spread of COVID-19 has caused illness, quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity, widespread unemployment, supply chain interruptions, and overall economic and financial market instability. All states have declared states of emergency and various states and cities have restricted commerce and travel to a varied degree.

We made the strategic and difficult decision to temporarily close all of our veterinarian service clinics effective March 20, 2020 to protect the health and safety of our employees, customers and retail partners. We began to reopen veterinary service locations in May 2020 and will continue the reopening, with 95% of wellness centers and mobile clinics reopened by September 30, 2020. This effort required developing a number of protocols, including curbside service at some locations, procurement of personal protective equipment, training of team members, and more to facilitate our ability to re-open. Pursuant to various State and Local executive orders and Public Health Departments, as well as the Department of Homeland Security and Centers for Disease Control and Prevention guidelines, it has determined that veterinary services are an essential business, and as such the Company does not expect an additional large scale disruption once it resumes activities.

The amount of the decrease in business that we will ultimately experience remains uncertain. This is largely due to: (i) existing concerns that many non-essential businesses and employees face permanent closure or heavy reliance on newly-established federal government programs, such as the Coronavirus Aid, Relief, and Economic Security Act of 2020 (CARES Act), in order to remain in operation and the ultimate success of these programs remains unknown; (ii) uncertainty of consumer/pet owner response and more specifically, the timing of engaged demand as the public is reintroduced to our retail environments as government restrictions are lifted or reduced; and (iii) absenteeism as it relates to employee symptoms, illness, and or exposure to COVID-19.

Our Products segment has remained in operation at our main three facilities in Springville, Utah, Omaha, Nebraska, and Daytona Beach, Florida, as well as our contract manufacturing partner in Plano, Texas. We have implemented a variety of policies and procedures to ensure the health and safety of our workforce, including staggering break times, adding additional shifts to enhance social distancing, enhancing sanitation procedures, providing personal protective equipment to employees, and requiring social distancing. We also provided a $2 an hour temporary wage increase for our production employees during the three and nine months ended September 30, 2020.

Our corporate and administrative personnel have been fully functional since we closed various administrative offices to employees and the general public, and implemented enhanced social distancing and work-from-home policies. A number of employees returned to these offices since we began re-opening, however a number of employees remain working remotely. We expect to continually review and adjust to local health conditions for the various jurisdictions in which we operate.

We are taking precautions to protect the safety and well-being of our employees while providing uninterrupted deliveries of products to our retailer partners. However, no assurance can be given that these actions will be sufficient, nor can we predict the level of disruption that will occur should the COVID-19 pandemic and its related macro-economic risks continue for an extended period of time. Additional information regarding risks and uncertainties to our business and results of operations related to the COVID-19 pandemic are set forth in Part II, Item 1A of this report.

Table of Contents

Results of Operations

The following tables set forth our consolidated statements of operations in dollars and as a percentage of net sales for the periods presented:


	For the Three Months Ended				% of Net Sales
$'s in 000's	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Product sales	$	150,063	$	161,534	92.6	%	86.8	%
Services revenue		12,020		24,491	7.4	%	13.2	%
Total net sales		162,083		186,025	100.0	%	100.0	%
Cost of products sold		116,847		140,839	72.1	%	75.7	%
Cost of services		12,968		17,895	8.0	%	9.6	%
Total cost of sales		129,815		158,734	80.1	%	85.3	%
Gross profit		32,268		27,291	19.9	%	14.7	%
General and administrative expenses		35,562		29,345	21.9	%	15.8	%
Contingent note revaluations loss		—		2,310	—	%	1.2	%
Operating loss		(3,294)		(4,364)	(2.0)	%	(2.3)	%
Interest expense, net		(7,829)		(5,742)	(4.8)	%	(3.1)	%
Foreign currency loss, net		(251)		—	(0.2)	%	—	%
Other income, net		13		6	0.0	%	0.0	%
Total other expense, net		(8,067)		(5,736)	(5.0)	%	(3.1)	%
Pretax net loss		(11,361)		(10,100)	(7.0)	%	(5.4)	%
(Provision) benefit for income taxes		(53,168)		1,304	(32.8)	%	0.7	%
Net loss	$	(64,529)	$	(8,796)	(39.8)	%	(4.7)	%


	For the Nine Months Ended				% of Net Sales
$'s in 000's	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Product sales	$	580,650	$	482,224	94.3	%	86.9	%
Services revenue		35,193		72,871	5.7	%	13.1	%
Total net sales		615,843		555,095	100.0	%	100.0	%
Cost of products sold		469,095		416,748	76.2	%	75.1	%
Cost of services		40,142		51,426	6.5	%	9.3	%
Total cost of sales		509,237		468,174	82.7	%	84.3	%
Gross profit		106,606		86,921	17.3	%	15.7	%
General and administrative expenses		105,744		74,333	17.2	%	13.4	%
Contingent note revaluation loss		—		3,090	—	%	0.6	%
Operating income		862		9,498	0.1	%	1.7	%
Interest expense, net		(18,500)		(9,921)	(3.0)	%	(1.8)	%
Foreign currency loss, net		(126)		(73)	(0.0)	%	(0.0)	%
Other income, net		702		21	0.1	%	0.0	%
Total other expense, net		(17,924)		(9,973)	(2.9)	%	(1.8)	%
Pretax net loss		(17,062)		(475)	(2.8)	%	(0.1)	%
Provision for income taxes		(52,060)		(77)	(8.5)	%	(0.0)	%
Net loss	$	(69,122)	$	(552)	(11.2)	%	(0.1)	%

Table of Contents

The following tables set forth financial information relating to the Company’s operating segments for the periods presented:


	For the three months ended				For the nine months ended
$'s in 000's	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Services segment sales:
Same-store sales	$	9,136	$	21,908	$	29,074	$	66,617
Non same-store sales		2,884		2,583		6,119		6,254
Net services segment sales		12,020		24,491		35,193		72,871
Products segment sales		150,063		161,534		580,650		482,224
Total net sales		162,083		186,025		615,843		555,095

Adjusted EBITDA
Products		26,318		20,506		92,448		56,030
Services		(223)		7,048		2,878		18,147
Unallocated Corporate		(14,088)		(8,296)		(40,555)		(23,217)
Total Adjusted EBITDA	$	12,007	$	19,258	$	54,771	$	50,960

Three Months Ended September 30, 2020 Compared With Three Months Ended September 30, 2019

Net sales

Consolidated Net Sales

Consolidated net sales decreased $23.9 million, or 12.9%, to $162.1 for the three months ended September 30, 2020, compared to $186.0 million for the three months ended September 30, 2019. This decrease was driven by the impact of COVID-19 related clinic closures on the services segment as well as some seasonal differences compared to the prior year in the products segment. Additionally during the three months ended September 30, 2020, a key retail partner aligned with the Company to transition a significant product program earlier than anticipated to fiscal 2021 which resulted in a loss of Products segment net sales of approximately $5 million.

Products Segment

Product sales decreased $11.5 million, or 7.1%, to $150.1 million for the three months ended September 30, 2020, compared to $161.5 million for the three months ended September 30, 2019. This decrease was driven by a seasonal acceleration of demand into the second quarter, with retailer customers drawing inventory down in the third quarter as well as the product program transition noted above.

Services Segment

Service revenue decreased $12.5 million, or 50.9%, from $24.5 million to $12.0 million for the three months ended September 30, 2020, compared to the three months ended September 30, 2019. Same-store sales decreased $12.8 million, or 58.3%, to $9.1 million for the three months ended September 30, 2020, compared to $21.9 million for the three months ended September 30, 2019. The decrease in same-store sales was driven by COVID-19 related closures. Non same-store sales increased $0.3 million or 11.7%, to $2.9 million for the three months ended September 30, 2020, compared to $2.6 million for the three months ended September 30, 2019. The increase in non same-store sales was a result of opening approximately 80 additional wellness centers in 2019, as well as the maturation of clinics opened in the past six trailing quarters, offset by the permanent closure of 15 wellness centers in the non-same store sales base and COVID-19 related closures.

Gross profit

Gross profit increased by $5.0 million, or 18.2%, to $32.3 million for the three months ended September 30, 2020, compared to $27.3 million for the three months ended September 30, 2019. This increase is due to growth in products manufactured in our Omaha Nebraska facility, which carry a higher margin than our distributed product sales.

Table of Contents

Additionally the Company experienced a minor benefit from the purchase of Capstar® during the quarter, which is now a PetIQ product.

Gross margin increased to 19.9% for the three months ended September 30, 2020, compared to 14.7% for the three months ended September 30, 2019. This increase was driven by product sales growth primarily in higher margin items, offset by service closures and related reopening of clinics.

General and administrative expenses

Consolidated general and administrative expenses (“G&A”) increased by $6.2 million, or 21.2%, to $35.6 million for the three months ended September 30, 2020, compared to $29.3 million for the three months ended September 30, 2019. As a percentage of net sales, G&A increased from 15.8% for the three months ended September 30, 2019 to 21.9% for the third quarter of 2020, primarily driven by integration costs related to centralization efforts, costs related to the addition of overhead to support the Omaha facilities, incremental amortization expense on the newly acquired intangible assets and general growth in corporate services to correspond with the growth in the Company. This increase is offset slightly by less acquisition costs.

Products Segment

Products segment G&A decreased $1.1 million or 11.7% to $8.3 million for the three months ended September 30, 2020, compared to $9.4 million for the three months ended September 30, 2019. This decrease was driven by improved absorption of overhead into our unit costs due to higher utilization of facilities and lower product specific marketing costs (total company marketing has increased).

Services Segment

Services segment G&A increased $0.5 million, or 10.9%, to $5.1 million for the three months ended September 30, 2020, compared to $4.6 million for the three months ended September 30, 2019. This increase was driven by increased wages as the Company re-opened service locations and continued to expand its development team to facilite continued new clinic rollouts, offset by COVID-19 related closures that reduced variable costs such as host fees, and bank charges.

Unallocated Corporate

Unallocated corporate G&A increased $6.8 million, or 44.4%, to $22.1 million for the three months ended September 30, 2020, from $15.3 million for the three months ended September 30, 2019. The increase was related to the following:

◾

Increased corporate marketing efforts for approximately $1.5 million;

◾

Additional corporate compensation (both stock compensation and wages/bonus) of approximately $4.4 million, partially driven by severance accruals for integration efforts;

◾

Increased professional fees of approximately $1.5 million, primarily related to the increased size of the Company, and Sarbanes Oxley compliance efforts;

◾

Increased amortization of $1.8 million resulting from the new acquisitions; and

◾

Other variable costs related to Company growth, such as insurance and information technology.

Interest expense, net

Interest expense, net, increased $2.1 million to $7.8 million for the three months ended September 30, 2020, compared to $5.7 million for the three months ended September 30, 2019. This increase was driven by the Notes issued in May 2020 to finance the Capstar Acquisition.

Provision for income taxes

Our effective tax rate was (468.0)% and 12.9% for the three months ended September 30, 2020 and 2019, respectively, with a tax expense of $53.2 million and a tax benefit of $1.3 million, respectively. The tax rate was driven by the valuation allowance recorded on the Company’s deferred tax assets in the current period. The Company’s tax rate is impacted by the ownership structure of Holdco, which changes over time.

Table of Contents

Segment Adjusted EBITDA

Products Segment

Products segment Adjusted EBITDA increased $5.8 million, or 28.3% to $26.3 million for the three months ended September 30, 2020, compared to $20.5 million for the three months ended September 30, 2019. Products segment Adjusted EBITDA fluctuates based on the quantity and mix of products sold, specifically whether the products are produced by PetIQ, or are distributed for other manufacturers. The significant growth in Products segment Adjusted EBITDA relates to significant sales growth of manufactured products, primarily produced at our Omaha facility, offset somewhat by lower seasonality in the current period (Q2 had a higher proportion of sales than in the previous year) and a customer product program transition occurring in the quarter.

Services Segment

Services segment Adjusted EBITDA decreased $7.2 million, to ($0.2) million for the three months ended September 30, 2020, compared to $7.0 million for the three months ended September 30, 2019. Services segment Adjusted EBITDA can fluctuate considerably for the Services segment based on the volume of pets seen in clinics, due to the relatively fixed cost nature of a clinic. Additionally, Services segment earnings are impacted by the Company’s growth strategy of opening new wellness centers and the impact of the Company’s same store portfolio, discussed further below. Services segment Adjusted EBITDA was significantly impacted by the COVID-19 closures and additional costs incurred related to re-opening, as well as converting some community clinics to wellness centers, which transitions operations into the non-same store category.

Unallocated Corporate

Unallocated corporate expenses consist of expenses incurred by centrally-managed departments, including accounting, legal, human resources information technology and headquarters expenses, as well as executive and incentive compensation expenses, and other miscellaneous costs. Unallocated corporate costs have primarily grown due to the growth in the Company, including adding to administrative headcount through acquisitions, as well as headquarters growth to support the larger Company. Adjustments to unallocated corporate include expenses related to specific events, such as the acquisition expenses, fair value of the inventory adjustment, integration costs, and the fair value adjustment to the contingent note. Adjustments also include non-cash expenses, such as depreciation, amortization, and stock based compensation.

The following tables reconcile Segment pre-tax net income to Adjusted EBITDA for the periods presented.


	Three months ended September 30, 2020
$'s in 000's	Products		Services		Unallocated Corporate		Consolidated
Pretax net income (loss)	$	25,117	$	(6,021)	$	(30,457)	$	(11,361)
Adjustments:
Depreciation		1,201		937		892		3,030
Interest		—		—		7,829		7,829
Amortization		—		—		3,821		3,821
Acquisition costs		—		—		1,083		1,083
Stock based compensation expense		—		—		2,147		2,147
Non same-store revenue		—		(2,884)		—		(2,884)
Non same-store costs		—		5,378		—		5,378
Integration costs and costs of discontinued clinics		—		—		307		307
Clinic launch expense		—		767		—		767
Litigation expenses		—		—		290		290
COVID-19 related costs		—		1,600		—		1,600
Adjusted EBITDA	$	26,318	$	(223)	$	(14,088)		12,007

Table of Contents


	Three months ended September 30, 2019
$'s in 000's	Products		Services		Unallocated Corporate		Consolidated
Pretax net income (loss)	$	10,376	$	2,991	$	(23,467)	$	(10,100)
Adjustments:
Depreciation		1,228		547		629		2,404
Interest		17		27		5,698		5,742
Amortization		—		—		1,807		1,807
Acquisition costs		—		—		1,960		1,960
Purchase accounting adjustment to inventory		2,403		—		—		2,403
Stock based compensation expense		—		—		1,601		1,601
Non same-store revenue		—		(2,583)		—		(2,583)
Non same-store costs		—		5,394		—		5,394
Fair value adjustment of contingent note		—		—		2,310		2,310
Integration costs and costs of discontinued clinics		—		—		1,166		1,166
Clinic launch expense		—		672		—		672
SKU Rationalization		6,482		—		—		6,482
Adjusted EBITDA	$	20,506	$	7,048	$	(8,296)		19,258

Nine Months Ended September 30, 2020 Compared With Nine Months Ended September 30, 2019

Net sales

Consolidated Net Sales

Consolidated net sales increased $60.7 million, or 10.9%, to $615.8 million for the nine months ended September 30, 2020, compared to $555.1 million for the nine months ended September 30, 2019. This increase was driven by the expansion of manufactured items as a result of the Perrigo Animal Health Acquisition, other growth in the Products segment related to distributed products led by the online channel, offset by declining sales in the Services segment due to COVID-19 related closures.

Products Segment

Product sales increased $98.4 million, or 20.4%, to $580.7 million for the nine months ended September 30, 2020, compared to $482.2 million for the nine months ended September 30, 2019. This increase was driven by accelerated growth in manufactured products led by those produced in our Omaha facility and by velocity growth within current customers of distributed products, specifically the online channel.

Services Segment

Service revenue decreased $37.7 million, or 51.7%, from $72.9 million to $35.2 million for the nine months ended September 30, 2020, compared to the nine months ended September 30, 2019. Same-store sales decreased $37.5 million, or 56.4%, to $29.1 million for the nine months ended September 30, 2020, compared to $66.6 million for the nine months ended September 30, 2019. The decrease in same-store sales was driven by COVID-19 related closures. Non same-store sales decreased $0.1 million or 2.2%, to $6.1 million for the nine months ended September 30, 2020, compared to $6.3 million for the nine months ended September 30, 2019. The decrease in non same-store sales was a result of opening approximately 80 additional wellness centers in the 2019 period, as well as the maturation of clinics opened in the past six trailing quarters, offset by the permanent closure of 15 wellness centers in the non-same store sales base and COVID-19 related closures.

Gross profit

Gross profit increased by $19.7 million, or 22.6%, to $106.6 million for the nine months ended September 30, 2020, compared to $86.9 million for the nine months ended September 30, 2019. This increase is due to the significant

Table of Contents

Products sales growth, and particularly in products manufactured in our Omaha Nebraska facility, which carry a higher margin than our distributed product sales, offset by a negative gross profit in services due to COVID-19 related closures.

Gross margin increased to 17.3% for the nine months ended September 30, 2020, from 15.7% for the nine months ended September 30, 2019, driven by product sales growth primarily in higher margin items, offset by the declines in Services due to COVID-19 related closures.

General and administrative expenses

Consolidated general and administrative expenses (“G&A”) increased by $31.4 million, or 42.3%, to $105.7 million for the nine months ended September 30, 2020, compared to $74.3 million for the nine months ended September 30, 2019. As a percentage of net sales, G&A increased from 13.4% for the nine months ended September 30, 2019 to 17.2% for the nine months ended September 30, 2020, primarily driven by a $7.8 million in expense related to the termination of a contract, costs related to the addition of overhead in and to support the Omaha facilities, and growth in corporate services.

Products Segment

Products segment G&A increased $3.2 million or 15.2% to $24.2 million for the nine months ended September 30, 2020, compared to $21.0 million for the nine months ended September 30, 2019. This increase was driven by acquisitions, resulting in approximately $6.4 million in G&A costs related to the acquired Perrigo Animal Health business in the first six months of the year, primarily selling and distribution expenses. This was offset by a reduction in other costs, like the centralization of certain functions like Company wide marketing to the corporate segment.

Services Segment

Services segment G&A decreased $0.3 million, or 2.5%, to $11.8 million for the nine months ended September 30, 2020, compared to $12.1 million for the nine months ended September 30, 2019. This decrease was driven by variable costs in supporting the Services revenue decreases due to COVID-19 closures, including host fees, marketing, and bank charges. Offset slightly due to growth from continuing to build the team

Unallocated Corporate

Unallocated corporate G&A increased $28.6 million, or 69.4%, to $69.8 million for the nine months ended September 30, 2020, from $41.2 million for the nine months ended September 30, 2019. The increase was related to the following:

◾

Increased corporate marketing efforts for approximately $6.2 million;

◾

Additional corporate compensation (both stock compensation and wages/bonus) of approximately $8.9 million, partially related to the severance accruals as part of integration activities;

◾

Increased professional fees and licensing costs, primarily related to the increased size of the Company, as well as Sarbanes Oxley compliance costs;

◾

Higher amortization on the inclusion of the Perrigo Animal Health Acquisition for the full year as well as new 2020 intangible asset acquisitions;

◾

A contract termination cost related to the transition from the Perrigo Animal Health Acquisition of $7.8 million, and

◾

Other variable costs related to Company growth, such as insurance and information technology.

Interest expense, net

Interest expense, net, increased $8.6 million to $18.5 million for the nine months ended September 30, 2020, compared to $9.9 million for the nine months ended September 30, 2019. This increase was driven by additional debt taken on to fund the Perrigo Animal Health Acquisition during 2019 as well as the Convertible Notes entered into during May 2020.

Table of Contents

Provision for income taxes

Our effective tax rate was (305.1)% and (16.3%) for the nine months ended September 30, 2020 and 2019, respectively, with a tax expense of $52.1 million and $0.1 million. The tax rate was driven by the valuation allowance recorded on the Company’s deferred tax assets in the current period. The Company’s tax rate is impacted by the ownership structure of Holdco, which changes over time.

Segment Adjusted EBITDA

Products Segment

Products segment Adjusted EBITDA increased $36.5 million, or 65.2% to $92.4 million for the nine months ended September 30, 2020, compared to $56.0 million for the nine months ended September 30, 2019. Products segment Adjusted EBITDA fluctuates based on the quantity and mix of products sold, specifically whether the products are produced by PetIQ, or are distributed for other manufacturers. The significant growth in Products segment Adjusted EBITDA relates to significant sales growth of manufactured products, primarily produced as the newly acquired Omaha facility.

Table of Contents

Services Segment

Services segment Adjusted EBITDA decreased $15.2 million, or 84.0%, to $2.9 million for the nine months ended September 30, 2020, compared to $18.1 million for the nine months ended September 30, 2019. Services segment Adjusted EBITDA can fluctuate considerably for the Services segment based on the volume of pets seen in clinics, due to the relatively fixed cost nature of a clinic. Additionally, Services segment earnings are impacted by the Company’s growth strategy of opening new wellness centers and the impact of the Company’s same store portfolio, discussed further below. Services segment Adjusted EBITDA was significantly impacted by the COVID-19 closures, as well as converting some community clinics to wellness centers, which transitions operations into the non-same store category.

Unallocated Corporate

The following tables reconcile Segment pre-tax net income to Adjusted EBITDA for the periods presented.


	Nine months ended September 30, 2020
$'s in 000's	Products		Services		Unallocated Corporate		Consolidated
Pretax net income (loss)	$	88,384	$	(16,853)	$	(88,593)	$	(17,062)
Adjustments:
Depreciation		3,685		2,674		2,527		8,886
Interest		—		—		18,500		18,500
Amortization		—		—		8,313		8,313
Acquisition costs		—		—		1,815		1,815
Stock based compensation expense		—		—		6,549		6,549
Non same-store revenue		—		(6,119)		—		(6,119)
Non same-store costs		—		15,476		—		15,476
Integration costs and costs of discontinued clinics		—		—		9,611		9,611
Clinic launch expense		—		2,046		—		2,046
Litigation expenses		—		—		723		723
COVID-19 related costs		379		5,654		—		6,033
Adjusted EBITDA	$	92,448	$	2,878	$	(40,555)	$	54,771

Table of Contents


$'s in 000's	Nine months ended September 30, 2019
September 30, 2019	Products		Services		Unallocated Corporate		Consolidated
Pretax net income (loss)	$	44,460	$	9,363	$	(54,298)	$	(475)
Adjustments:
Depreciation		2,134		1,591		1,862		5,587
Interest		51		85		9,785		9,921
Amortization		—		—		4,364		4,364
Acquisition costs		—		—		5,425		5,425
Stock based compensation expense		—		—		4,747		4,747
Purchase accounting adjustment to inventory		2,403		—		—		2,403
Non same-store revenue		—		(6,254)		—		(6,254)
Non same-store costs		—		12,690		—		12,690
Fair value adjustment of contingent note		—		—		3,090		3,090
Integration costs and costs of discontinued clinics		500		—		1,808		2,308
Clinic launch expense⁽⁵⁾		—		672		—		672
SKU Rationalization		6,482		—		—		6,482
Adjusted EBITDA	$	56,030	$	18,147	$	(23,217)	$	50,960

Consolidated Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA are non-GAAP financial measures. EBITDA represents net income before interest, income taxes and depreciation and amortization. Adjusted EBITDA represents EBITDA plus adjustments for transactions that management does not believe are representative of our core ongoing business. Adjusted EBITDA is utilized by management: (i) as a factor in evaluating management’s performance when determining incentive compensation and (ii) to evaluate the effectiveness of our business strategies. The Company presents EBITDA because it is a necessary component for computing Adjusted EBITDA.

We believe that the use of EBITDA and Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends. In addition, you should be aware when evaluating EBITDA and Adjusted EBITDA that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by these or other unusual or non-recurring items. Our computation of EBITDA and Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate EBITDA and Adjusted EBITDA in the same manner.

Our management does not, and you should not, consider EBITDA or Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of EBITDA and Adjusted EBITDA is that they exclude significant expenses and income that are required by GAAP to be recorded in our financial statements. Some of these limitations are:

●	EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

●	EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

●	EBITDA does not reflect the interest expenses, or the cash requirements necessary to service interest or principal payments, on our debts;

●	although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements;

Table of Contents

●	Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of our ongoing core operations; and

●	Other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Because of these limitations, EBITDA and Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using EBITDA and Adjusted EBITDA only supplementally. You should review the reconciliations of net (loss) income to EBITDA and Adjusted EBITDA below and not rely on any single financial measure to evaluate our business.

The following table reconciles net loss to EBITDA and Adjusted EBITDA for the periods presented.


	For the three months ended				For the nine months ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Net loss	$	(64,529)	$	(8,796)	$	(69,122)	$	(552)
Plus:
Tax expense (benefit)		53,168		(1,304)		52,060		77
Depreciation		3,030		2,404		8,886		5,587
Amortization		3,821		1,807		8,313		4,364
Interest		7,829		5,742		18,500		9,921
EBITDA	$	3,319	$	(147)	$	18,637	$	19,397
Acquisition costs⁽¹⁾		1,083		1,960		1,815		5,425
SKU Rationalization⁽²⁾		—		6,482		—		6,482
Stock based compensation expense		2,147		1,601		6,549		4,747
Purchase accounting adjustment to inventory		—		2,403		—		2,403
Non same-store revenue⁽³⁾		(2,884)		(2,583)		(6,119)		(6,254)
Non same-store costs⁽³⁾		5,378		5,394		15,476		12,690
Fair value adjustment of contingent note⁽⁴⁾		—		2,310		—		3,090
Integration costs and costs of discontinued clinics⁽⁵⁾		307		1,166		9,611		2,308
Clinic launch expenses⁽⁶⁾		767		672		2,046		672
Litigation expenses		290		—		723		—
COVID-19 related costs⁽⁷⁾		1,600		—		6,033		—
Adjusted EBITDA	$	12,007	$	19,258	$	54,771	$	50,960

(1)	Acquisition costs include legal, accounting, banking, consulting, diligence, and other out-of-pocket costs related to completed and contemplated acquisitions.

(2)

SKU rationalization relates to the disposal of or reserve to estimated net realizable value for inventory that will either no longer be sold, or will be de-emphasized, as the Company aligns brands between Legacy PetIQ brands and brands acquired as part of the Perrigo Animal Health Acquisition. All costs are included in the Products segment gross margin.

(3)	Non same-store revenue and costs relate to our Services segment and are from wellness centers, host partners, and regions with less than six full trailing quarters of operating results.

(4)	Fair value adjustment on the contingent note represents the non cash adjustment to mark the 2019 Contingent Note to fair value.

(5)

(6)	Clinic launch expenses relate to our Services segment and represent the nonrecurring costs to open new veterinary wellness centers, primarily employee costs, training, marketing, and rent prior to opening for business.

Table of Contents

(7)

Financial Condition, Liquidity, and Capital Resources

Historically, our primary sources of liquidity have been cash flows from operations, borrowings, and equity capital. As of September 30, 2020 and December 31, 2019, our cash and cash equivalents were $57.8 million and $27.3 million, respectively. As of September 30, 2020, we had $15.0 million outstanding under a revolving credit facility, $217.8 million under a term loan, $143.8 million of outstanding Notes, and $44.5 million in other debt. Our debt agreements bear interest at rates between 2.3% and 6.75%.

Our primary cash needs are for working capital. Our maintenance capital expenditures have typically been less than 1.0% of net sales, but we may make additional capital expenditures as necessary to support our growth, such as the investment in additional veterinary clinics. Our primary working capital requirements are to carry inventory and receivable levels necessary to support our increasing net sales. Fluctuations in working capital are primarily driven by the timing of new product launches and seasonal retailer demand. As of September 30, 2020 and December 31, 2019, we had working capital (current assets less current liabilities) of $146.9 million and $112.4 million, respectively.

Additionally, the Company acquired the U.S. rights to Capstar® and CapAction® and related assets (the “Acquisition”) from Elanco, US Inc. for $95 million, plus the cost of certain outstanding finished goods inventory in saleable condition. The Acquisition closed on July 31, 2020 and was financed using cash from the sale of the Notes in May 2020.

We believe that our operating cash flow, cash on hand, and debt proceeds from our borrowings under our credit facility will be adequate to meet our operating, investing, and financing needs for the foreseeable future. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.

Cash Flows

Cash used in Operating Activities

Net cash provided by operating activities was $13.8 million for the nine months ended September 30, 2020, compared to cash used in operating activities of $8.6 million for the nine months ended September 30, 2019. The change in operating cash flows primarily reflects lower earnings which were driven by non cash charges and increased cash provided by changes in working capital items. Working capital changes are driven by slowing accounts receivable growth and growth in accounts payable. Net changes in assets and liabilities accounted for $4.2 million in cash used in operating activities for the nine months ended September 30, 2020 compared to $27.1 million of cash used in operating activities for the nine months ended September 30, 2019.

Cash used in Investing Activities

Net cash used in investing activities was $113.5 million for the nine months ended September 30, 2020, compared to $190.1 million for the nine months ended September 30, 2019. The decrease in net cash used in investing activities is a result of the purchase of Perrigo Animal Health, offset by the current Acquisition of Capstar®.

Cash provided by Financing Activities

Net cash provided by financing activities was $130.2 million for the nine months ended September 30, 2020, compared to $142.9 million for the nine months ended September 30, 2019. The change in cash provided by financing activities is primarily driven by the Company’s the issuance of Notes and the purchase of Capped call options, compared to financing obtained for the purchase of Perrigo Animal Health. During the nine months ended September 30, 2020, we

Table of Contents

received $137.9 million of proceeds from the issuance of 4.0% Convertible Senior Notes Due 2026 (the “Notes”), net of issuance costs, paid $14.8 million for privately negotiated convertible note hedge transactions (“Capped Call”).

Description of Indebtedness –

Convertible Notes

In accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated using a discount rate of 13%, which was determined by measuring the fair value of a similar debt instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was $53.3 million and was determined by deducting the fair value of the liability component from the par value of the Notes. The excess of the principal amount of the liability component over its carrying amount, or the debt discount, is amortized to interest expense at an annual effective interest rate over the contractual terms of the Notes.

Table of Contents

A&R Credit Agreement

A&R Term Loan Credit Agreement

Table of Contents

General Other Debt

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We are exposed to certain market risks arising from transactions in the normal course of our business. Such risk is principally associated with interest rates. We currently do not enter into derivatives or other financial instruments for trading or speculative purposes.

Interest Rate Risk

We are exposed to changes in interest rates because the indebtedness incurred under our A&R Credit Agreement and A&R Term Loan Credit Agreement are variable rate debt. Interest rate changes generally do not affect the market value of our credit agreement but do affect the amount of our interest payments and, therefore, our future earnings and cash flows. As of September 30, 2020, we had variable rate debt of approximately $232.8 million under our Revolver and Term Loan. An increase of 1% would have increased our interest expense for the nine months ended September 30, 2020 by approximately $3.1 million.

Item 4. Controls and Procedures.

Internal Control over Financing Reporting

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that as of such date, our disclosure controls and procedures were effective.

Table of Contents

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during our fiscal quarter ended September 30, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that some of our corporate employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the impact of COVID-19 on our internal controls to minimize the impact on their design and operating effectiveness.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could” and similar expressions. Examples of forward-looking statements include, without limitation:

●	statements regarding our strategies, results of operations or liquidity;

●	statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance;

●	statements of management’s goals and objectives; and

●	assumptions underlying statements regarding us or our business.

Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, factors discussed under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations” the impact of COVID-19 on our business and the global economy; our ability to successfully grow our business through acquisitions; our dependency on a limited number of customers; our ability to implement our growth strategy effectively; disruptions in our manufacturing and distribution chains; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to manage our manufacturing and supply chain effectively; disruptions in our manufacturing and distribution chains; our ability to introduce new products and improve existing products; our failure to protect our intellectual property; costs associated with governmental regulation; our ability to keep and retain key employees; our ability to sustain profitability; and the risks set forth under the “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019 our Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020, this Report and other reports filed from time to time with the Securities and Exchange Commission.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We are from time to time subject to, and are presently involved in, litigation and other proceedings. Other than the litigation described below, we believe that there are no pending lawsuits or claims that, individually or in the aggregate, may have a material adverse effect on our business, financial condition or results of operations.

As previously disclosed, on April 4, 2018, Med Vets, Inc. and Bay Medical Solutions Inc. (collectively “Plaintiffs”) filed suit in the United States District Court for the Northern District of California against PetIQ and VIP Petcare Holdings, Inc. for alleged unlawful merger and other antitrust violations. On June 29, 2020, the 9^th Circuit Court of Appeals issued an opinion affirming the dismissal of Med Vets’ merger challenge. On July 13, 2020, the Plaintiffs filed for an en banc hearing in the 9^th Circuit Court of Appeals which was unanimously denied on August 7, 2020. As no impact to the Company is considered probable or estimable, no litigation reserve has been accrued.

The Company records a liability when a particular contingency is probable and estimable and provides disclosure for contingencies that are at least reasonably possible of resulting in a loss including an estimate which we currently cannot make. The Company has not accrued for any contingency at September 30, 2020, as the Company does not consider any contingency to be probable or estimable. The Company expenses legal costs as incurred within general and administrative expenses on the consolidated statements of operations.

Item 1A. Risk Factors.

There have been no material changes to the risk factors disclosed in our annual report on Form 10-K for the year ended December 31, 2019, except for the risk factor updated below:

The scale and scope of the recent COVID-19 outbreak and resulting pandemic is unknown and, due to wellness center and community clinic closures and other factors, is likely to result in an adverse impact on our business at least for the near term.

As the U.S. faces the novel COVID-19 pandemic, the Company is following the recommendations of government and health authorities to minimize exposure for its veterinarians, associates, customers and retail partners. As a result, the Company announced on March 19, 2020 that it temporarily closed all of its veterinary community clinics and wellness centers effective Friday, March 20, 2020, 95% of which had reopened as of September 30, 2020. The Company will closely monitor this global health crisis to reopening its community clinics and wellness centers as quickly as practical. The Company will continue to reassess its strategy on a regular, ongoing basis as the situation evolves. Additionally, the rapid spread of COVID-19 globally also has resulted in travel restrictions and disruption and shutdown of certain businesses in the U.S., including those of certain of our retail partners. We may experience impacts from changes in customer behavior related to pandemic fears, quarantines and market downturns, as well as impacts on our workforce if the virus becomes widespread in any of our markets. For example, the Company has experienced an elevated level of absenteeism due to COVID-19 related illnesses and as a result between 12% and 16% of service segment operations are temporarily closed week to week. If the virus were to affect a significant amount of the workforce employed or operating at our facilities, we may experience delays or the inability to produce and deliver products to our retail partners on a timely basis. In addition, one or more of our customers, service providers or suppliers may experience financial distress, file for bankruptcy protection, go out of business, or suffer disruptions in their business due to the COVID-19 outbreak. The global scale and scope of COVID-19 is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. The extent to which the coronavirus impacts the Company’s results will ultimately depend on future developments, which are highly uncertain and will include the duration of our wellness center and community clinic closures as well as closures of our retail partners, emerging information concerning the severity of COVID-19 and the actions taken by governments and private businesses to attempt to contain COVID-19. However, the Company believes COVID-19 is likely to result in an adverse impact on our business, results of operations and financial condition, at least for the near term.

Table of Contents

Item 6. Exhibits. –


31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document.
104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)

* Filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	PETIQ, INC.

November 6, 2020	/s/ John Newland
	John Newland
	Chief Financial Officer